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Tuberkulose: infeksjon og sykdom hos asylsøkere i Norge. 
Screening og oppfølging i det offentlige helsevesen.¨ 
 
 
Årlig får åtte millioner mennesker i verden tuberkulose. En regner med at en tredjedel av 
verdens befolkning er smittet (latent tuberkulose), og av disse blir omtrent en av ti syke.  
I Norge får omkring 300 personer tuberkulose hvert år og over 80 % av pasientene er fra 
land hvor tuberkulose fortsatt er vanlig. I henhold til norske retningslinjer skal alle 
asylsøkere som kommer til landet undersøkes like etter ankomst med tuberkulintest og 
røntgen av lungene for å se om de er syke eller smittet av tuberkulose. Ved forhøyet 
tuberkulintest skal de vurderes i kommunehelsetjenesten eller henvises direkte til 
spesialist. Dersom røntgenbildene gir mistanke om tuberkulose, skal de undersøkes av 
spesialist før de sendes videre i mottakssystemet.  
Målet med studien var å finne ut hvordan screeningen fungerer; blir alle 
undersøkt, blir alle med forandringer på lungerøntgen eller forhøyet tuberkulintest fulgt 
opp, og hva er resultatet av oppfølgingen? I tillegg ble det gjort en vurdering av om en 
spesiell blodanalyse kunne være av nytte i screeningen. 
Data fra alle asylsøkere som kom til Norge i 2005-2006 ble gjennomgått. Alle 
som enten hadde forhøyet tuberkulintest eller forandringer på lungerøntgen ble fulgt opp 
ved å sende spørreskjema til helsevesenet. Senere ble data for alle disse krysset mot 
Tuberkuloseregisteret hvor alle som enten har fått påvist sykdommen tuberkulose eller 
fått behandling for latent tuberkulose er registrert.   
Halvparten av asylsøkerne, 2237 personer, som kom i den aktuelle perioden 
hadde positive funn ved ankomstscreening og ble derfor inkludert i studien. 
Tuberkulintest var registrert hos 97,5% mens opplysninger om røntgenbilde var tatt, ikke 
var registrert i personenes medisinske journal. Blant asylsøkere med forandringer på 
lungerøntgen var 2/3 blitt fulgt opp av spesialist, mens 1/3 var blitt vurdert i 
primærhelsetjenesten.  
Aktiv tuberkulose som et resultat av screeningen ble påvist hos 15 personer, og 28 
fikk behandling for latent tuberkulose. Det var ingen sammenheng mellom alvorlighets- 
grad av screeningfunn og om personen ble undersøkt i kommunehelsetjenesten. Kvinner 
fra Somalia hadde økt risiko for å få tuberkulose. Personer med sterkt positiv 
tuberkulintest hadde økt sjanse for å få behandling for latent tuberkulose. 
En stor andel av asylsøkerne som hadde tuberkulose ved ankomst til landet ble 
diagnostisert raskt gjennom screeningprogrammet. Imidlertid var det mange med 
røntgenfunn som ikke fikk noen diagnose. I kommunehelsetjenesten var det svært 
variabel grad av oppfølging og dårlige rutiner for oppbevaring av helseinformasjon. 
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Summary 
Introduction 
About 80% of new tuberculosis (TB) cases in Norway occur among immigrants from 
high incidence countries in Africa, Asia and Eastern Europe, and most of them are 
infected on arrival.  Tuberculosis screening of immigrants from such countries is 
compulsory with a Mantoux test of everybody and a chest X-ray of all above 15 years 
of age.  The aim of the screening is to identify cases of active tuberculosis in order to 
give treatment and stop transmission of the disease, and to offer treatment or follow-
up for cases with latent tuberculosis. 
Asylum seekers are screened at the National Reception Centre in Oslo before they are 
transferred to other asylum seekers centres or relocated to municipalities around the 
country.  Internationally, there is an ongoing discussion about screening of 
immigrants, as well as the indications for treatment of latent tuberculosis. 
Aim 
The aim of the study was to assess the conduct of entry screening among asylum 
seekers, and the follow-up of results for active and latent tuberculosis.  A secondary 
aim was to assess the predictive properties of QuantiFERON-TB Gold (QFT) as a 
potentially new screening tool for tuberculosis disease. 
Methods 
All asylum seekers above the age of 18 who arrived at the National Reception Centre 
from January 2005 to June 2006 were eligible for inclusion in the follow-up study.  
They were included if they had either a Mantoux test  6 mm, a positive chest X-ray, 
or a positive QFT test.  The latter regarded the subset of asylum seekers who arrived 
between September 2005 and June 2006.  Potential participants were excluded if they 
left the Reception Centre without a new address or left the country directly.  
Information about the study and a data collection form were sent to the health 
authorities in the municipalities where the asylum seekers moved to.  In case anyone 
had moved on to another municipality in the meantime, the same information and 
study form were sent to the authorities in their new place of residence.  If we received 
information that a study participant had been referred to specialist health care, a 
second form was sent to the health institution in question.  All included study subjects 
were later matched with the National Tuberculosis Register which contains 
information about everybody diagnosed with active tuberculosis, or who have started 
treatment for latent tuberculosis. 
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An additional aim of the study of the above mentioned subsample, was to compare 
QFT and the Mantoux test.  Everyone with a valid QFT test result where name and 
birth date were available were later matched with the National TB Register. 
 
Results 
Of 4643 available asylum seekers, 2237 were included in the follow-up study.  We 
found a valid Mantoux test result in 97.5% of them.  We were on the other hand 
unable to ascertain and document the exact number of X-rays that were taken at the 
Reception Centre.  Fifteen cases of tuberculosis, mainly pulmonary TB, were 
identified through the screening programme within two months after arrival.  
Altogether 28 cases of active TB had been diagnosed by the end of May 2008.  
Female gender, Somalian origin and a positive X-ray on arrival were all associated 
with active tuberculosis. 
Of 314 persons with a positive X-ray, 62% had been seen by an internist in order to 
get a conclusive diagnosis.  Similarly, of 568 asylum seekers with a Mantoux  
15mm, 16% had been examined by a specialist.  Only one third of persons with an 
elevated Mantoux test had been assessed at the community level and there was no 
association between the characteristics of the screening result (positive X-ray, and 
size of Mantoux) and the probability of being assessed.  
Altogether 30 cases of latent TB were started on treatment, which took place a median 
17 months (range 3-36) after arrival.  A Mantoux  15mm was the only characteristic 
that was associated with treatment induction.  
The positive and negative predictive values (PPV and NPV, respectively) for 
Mantoux and QFT were the same.  The negative predictive value for a Mantoux  
6mm in combination with a negative QFT was as good as the NPV for Mantoux 
<15mm alone. 
Conclusion 
The conduct of the screening programme for asylum seekers was by no means in 
accordance with the official guidelines.  Asylum seekers were screened with Mantoux 
on arrival, but we were unable to document the exact number who had been screened 
with chest X-ray.  The main concern is the lack of a specialist examination of persons 
with a positive X-ray, but also of persons with a Mantoux  15mm.  Compared to 
other studies, a reasonable number of cases were diagnosed with active TB within 2 
months after the arrival screening.  Two cases were diagnosed from 3-6 months after 
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arrival and were probably missed by screening, but an unknown number of cases may 
have been lost because of insufficient follow-up of X-ray results.  Six of eight cases of 
extra-pulmonary TB were diagnosed more than four months after arrival and could 
well have been ill for months before diagnosis.  At the primary health care (PHC) 
level there was an obvious lack of a common strategy for taking responsibility for the 
follow-up of TB screening results.  
A secondary finding was that QFT was as precise as Mantoux in predicting TB, and 
the negative predictive values for a Mantoux  6mm with a negative QFT were 
equally as precise as for a negative Mantoux alone. 
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1: Introduction 
1.1: Tuberculosis epidemiology 
 
The global burden of tuberculosis 
Since 1997 WHO has made a yearly assessment of the global TB epidemic and the 
effect of control measures.  For the year 2007 the organisation estimated a total of 
9.27 million new (incident) and 13.7 million existing (prevalent) cases of tuberculosis 
worldwide (1).  More than half (55%) of the new cases occurred on the Asian 
continent and 31% in Africa.  The fact that 13 of the 15 countries with the highest 
incidence rates were located in Africa (Figure 1) is probably due to the simultaneous 
high rate of TB and HIV infection on the continent.  Among new TB cases in 2007, 
4.1 million were estimated to be smear positive and 1.4 million to be HIV positive.  
Further, 500 000 individuals were estimated to have multi-drug resistant TB (MDR-
TB), i.e. the bacteria were resistant to both isoniazid and rifampicin.  WHO has also 
estimated that 1.3 million of HIV-negative and about 450 000 HIV-positive TB cases 
died of their disease in 2007 (1).   
 
 
Figure 1. Estimated TB incidence rates by country, 2007.  
Reprinted with permission from WHO report 2009: Global tuberculosis control (1). 
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Roughly estimated one third of the world’s population has been infected with 
tuberculosis (2).  However, there is a great diversity between countries, and in rural 
India 80% of the population had a positive interferon- release assay (IGRA) test (3). 
Around 1% had a positive TST in a study among Western teenagers born in Norway,   
and only 6% of these had a positive IGRA test (4). 
 
The targets for the millenium development goals (MDG) for global TB control are: 1) 
to stop the overall increase and start reducing the incidence of TB by 2015, 2) to 
reduce the prevalence and death rates by 50% in 2015 compared to 1990, 3) to 
successfully treat at least 85% of patients with active tuberculosis, and 4) to detect and 
treat 70% of smear positive cases through directly observed treatment, short course 
(DOTS) programmes.  The DOTS programme includes a) political commitments, b) 
case detection by bacteriological examination of symptomatic patients reporting to the 
primary health care, c) standardised treatment with supervision and patient support, d) 
an effective drug supply system, and e) a monitoring and evaluation system (1, 5).   
  
The incidence rates, prevalence and mortality rates have fallen globally since 2004, 
but are still not expected to be halved in all regions by 2015 as is the MDG.  In 2007 
the global treatment success rate was 85%, and 63% of smear positive cases were 
detected and treated under DOTS programmes (1).  In general, the African and 
European regions (including the former Soviet Union) had the lowest success rates.  
 
Tuberculosis in Norway  
Around the year 1900 about 6000 people died yearly of tuberculosis in Norway.  In 
1920 the incidence of pulmonary TB was 300/100 000 in the population(Figure 2), 
and a study in 1927-1928 by Heimbeck showed that 100% of working class people 
were infected before they reached the age of 30 (6).  The number of new cases 
declined steadily from around 1920 until the late 1980s (Figure 2).  For example in 
1945 3814 new cases were registered which gave an incidence rate (IR) of 125/100 
000 for that year for the population as a whole (7).  
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Figure 2. Mortality from TB and incidence from infectious pulmonary TB in 
Norway.  Reprinted with permission from E. Heldal (8)  
 
In the mid 1970s around four percent of new cases occurred among persons who were 
born outside Norway (9).  That proportion increased from 66% in 1999 to 79% in 
2007 (10) (Figure 3).  Another typical trend is that the majority of the foreign born 
cases were young persons.  For instance, in 2007 the median age of new cases was 29 
years which was clearly different from the median age of 74 years for new cases 
diagnosed among the ethnic Norwegian population (10).  In 2007 the overall IR in 
Norway was 6.5/100 000 inhabitants, yet it was 1.5/100 000 and 54.6/100 000 for 
Norwegian and foreign born individuals, respectively (10).  Since the year 2000 three 
to four new cases of MDR-TB  have been registered each year, mainly among people 
who come from Eastern Europe (11).  Altogether three cases of extensive drug 
resistant TB (XDR-TB) where the bacteria are resistant to at least isoniazid, 
rifampicin, a fluoroquinolone, and either amikacin, kanamycin or capreomycin, have 
been registered in Norway (11).  Molecular studies have suggested that most cases of 
TB were due to imported strains and that about 80% of the cases were reactivation of 
previously contracted TB infection (12). 
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Figure 3. Incidence of TB in Norway by status of origin. 1977 – 2009 
Information obtained from the National Tuberculosis Register 
 
1.2: Migration, refugees and asylum seekers 
People migrate between countries for many different reasons.  According to the 
United Nations (UN), the total world population was 6.5 billion in 2005 of whom a 
total of 190 millions were international migrants.  Roughly 64 million immigrants 
lived in Europe and 44 millions in North America (13). 
 
Based on information from the High Commissioner for Refugees in the same year 
(2005), there were an estimated number of 13 millions refugees (13).  Classification 
of different immigrant groups such as refugees, asylum seekers, immigrant workers 
and others may differ between countries and is in most cases a question about legal 
status.  In Norway asylum seekers are defined as such if they have asked for 
protection and recognition as a refugee.  Refugees on the other hand are those who 
already have been granted protection (14).   
 
A European TB study has estimated that the proportion of undocumented migrants 
varies greatly (5-30%) between countries (15).  The total number of such immigrants 
was 5-8 million and they represented 5-10% of all TB cases. 
 
In 2005 the total Norwegian population was 4 606 363.  Among them, 176 089 (3.8%) 
were immigrants from Asia, Africa, South- America, or Turkey (16).  The immigrants 
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had come either as UN refugees, asylum seekers, for family reunion or they were 
labour immigrants or students.  Altogether 54 256 immigrants came from Eastern 
Europe.  Still, the most frequent countries of origin were Pakistan, Iraq and Somalia 
(16).  
   
1.3: Tuberculosis control programmes 
 
Tuberculosis control programmes in Norway 
The occurrence of tuberculosis increased during the last part of the 19th century, and 
in 1900 the first enactment about tuberculosis was passed (17).  It became mandatory 
to report all cases of tuberculosis to the community health board that could decide 
about isolation of cases, prohibit persons with tuberculosis to do certain kinds of 
work, and carry out contact tracing.  In some cases the public authorities would pay 
for a patient’s stay in a sanatorium.  The general aim of the law was to protect the 
public from persons with infectious disease and to control transmission of infection.  
General cleanliness, nourishing food and fresh air were advised both to protect 
healthy people and to cure patients.  Extensive health education campaigns were 
performed both by non governmental organisations (NGOs) and public health 
officials.  One well known part of the campaign was posters with a message against 
spitting.  The number of sanatoria gradually increased, and in the 1920s and -30s 
treatment of patients became gradually more important.  In particular, surgical 
procedures that aimed to limit the disease of individual patients were increasingly 
performed (17).   
  
In 1927 the BCG vaccine was introduced in a study among voluntary nursing students 
in Oslo (6).  The vaccine was compulsory for school children (12-14 years old) from 
1947 until 1995.  Since then it is being recommended (11).  BCG vaccination of 
newborn children of parents from high incidence countries has been recommended for 
many years (11). 
 
In 1947 a new enactment on tuberculosis became effective.  This included mandatory 
BCG vaccination (see above), tuberculin testing of certain groups, and mass 
radiography screening of adults (18).  However, the National Mass Radiography 
service had already started in 1943 and gradually covered the whole adult population 
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(19).  The aim was to stop the transmission of TB through early case finding.  From 
1966 to 1974 the public health approach changed from a general to a risk based 
selection of people for X-ray screening (20).  From the mid 1990s on, chest X-ray 
screening is only used for selected groups, i.e. for contact tracing and for other groups 
with an increased risk (21).    
 
The number of new cases has decreased continuously since 1900.  This occured 
during a time period when TB laws and corresponding preventive measures were 
introduced, the social conditions were improved, and immunisation of the population 
started.  After the Second World War modern drug treatment was introduced and this 
further reduced the transmission of infection (18).  In the 1950s and -60s the number 
of TB cases, both new and existing, declined dramatically.  During that same period 
most of the specialized TB care became an integrated part of regular health care 
provision (18).  
 
In 1956 screening for TB became compulsory for foreigners who applied for work in 
Norway, and in 1977 for all immigrants from high incidence countries. 
 
Tuberculosis control programme during the study period 
New governmental regulations about TB screening and treatment were issued in 2002 
(22).  They emphasised that screening of high risk groups was mandatory.  The aim of 
these regulations was to prevent transmission of infection and development of disease 
in infected persons.  In addition, teachers and health care personnel returning from 
long-term stays in high incidence countries must also be screened in order to avoid 
that they transmit a possible infection to vulnerable groups (22).  The need for 
treatment for latent TB was underscored, yet the guidelines did not state what the 
definite treatment indications for latent TB are.  For patients from high incidence 
countries treatment is recommended when the chest X-rays have fibrotic 
abnormalities, and treatment should be considered when the Mantoux test is elevated.  
Before treatment for latent infection is decided, a history of previous tuberculosis, the 
risk of recent infection, relevant clinical symptoms, the result of chest X-ray, the size 
of the Mantoux test, and other risk factors must be weighed against treatment 
contraindications and the patients age (23).   
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Local health authorities are responsible for TB screening of all refugees, persons who 
arrive for family reunion as well as other immigrants from high TB incidence 
countries when they arrive in their municipalities.  The screening programme is 
organised differently for asylum seekers than for other groups of immigrants, but 
includes the same procedures.  They are a Mantoux test for all regardless of age, and a 
chest X-ray for everybody above the age of 15.  An interview about previous 
tuberculosis disease and relevant symptoms is compulsory, but the guidelines do not 
state where this interview should be performed.  Nevertheless, a positive X-ray and/or 
a Mantoux test  15mm, previous TB, or any symptoms of the disease shall lead to a 
direct referral to specialist health care.  A Mantoux test result between 6 and 14mm 
shall be assessed by a local public health physician.  In the latter case and based on all 
available information, the patient shall be referred to specialist care whenever 
clinically indicated.   
 
Patients are referred to the local hospital, most often to the department of pulmonary 
medicine, department of paediatrics (persons under 18 years), department of 
infectious diseases, or general internal medicine.  The hospital specialist will also take 
a history, for which an interpreter is often required, and then conduct a clinical 
examination which usually includes a sputum test.  A repeat chest X-ray is most often 
taken.  The final decision will be a) to start treatment for active tuberculosis, b) start 
treatment for latent tuberculosis, c) that further observation is necessary, or d) that no 
treatment or follow-up is needed.  If active tuberculosis is diagnosed or treatment for 
latent tuberculosis is started, a nominal notification is sent to the Norwegian National 
Tuberculosis Register. 
 
Tuberculosis control programmes in other low incidence countries 
There is no uniform policy for TB control programmes in low incidence countries, 
which is defined as countries with less than 10 new cases of tuberculosis per 100 000 
population per year.  In Western Europe most countries have given universal BCG 
vaccination, but as the TB epidemic declined in the general population, they have 
gradually stopped doing it or concentrated their efforts on high risk groups (11).  A 
study that covered the European region of WHO, included the former Soviet Union, 
was performed in 2004.  The response rate was quite low (26 of 51 countries 
responded).  However, 50% of the countries who did respond, confirmed that they 
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carried out some kind of screening for new entrants, i.e. all of them screened refugees, 
but none carried out pre-entry screening (24).  All of the reported programmes used 
chest X-ray as a screening tool, but none had the same clinical approach.  Tuberculin 
testing (TST) was used in ten countries, whereas eight treated certain groups of cases 
with latent tuberculosis (24).  Another study from 2006 evaluated several screening 
units in Norway, the UK, the Netherlands and Switzerland (25).  This study showed 
considerable variations in screening services offered, i.e. between centres as well as 
countries.  In general, few output data were routinely and systematically collected 
(25).  Neither USA nor Canada have introduced BCG vaccination in their 
programmes, but have instead treated latent tuberculosis more extensively (26).  
Together with Australia, these two countries have implemented pre-entry screening 
for immigrants (26). 
 
1.4: The National Tuberculosis Register 
The National Institute of Public Health is responsible for surveillance of transmittable 
diseases in Norway and the National Tuberculosis Register is part of that surveillance.  
All cases of suspected or verified tuberculosis disease or TB cases that have started on 
treatment are nominally reported to the register.  Both clinicians and medical 
laboratories that diagnose TB have an obligation to notify individual cases.  Also 
patients who have started on treatment for latent TB must be registered.  For quality 
assurance purposes this register is regularly matched with the register of TB drugs at 
the National Hospital Pharmacy where all prescriptions are handled.  
 
1.5: Relocations of asylum seekers and screening for tuberculosis 
Arrival screening 
Almost every person who seeks political asylum in Norway is admitted via the 
National Reception Centre at Tanum outside Oslo.  Any acute medical needs and 
legal issues are attended to.  The compulsory tuberculosis screening with a Mantoux 
test and chest X-ray is also done here (Table 1 & Figure 4).  Asylum seekers are only 
interviewed about health issues or given a clinical examination if they have acute or 
serious medical complaints.  A test for HIV is not compulsory, but taken if clinically 
relevant.  Asylum seekers spend on average between five days and two weeks at the 
Reception Centre.  Normally they leave when the X-ray results have been cleared.  
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Figure 4. Description of relocations of asylum seekers, and referrals, and 
notification of confirmed or suspected cases of tuberculosis disease 
 
In case of any clinical symptoms or X-ray findings that may be related to tuberculosis, 
the persons in question are referred to the Central TB Clinic at Ullevål University 
Hospital in Oslo.  The main focus here is to rule out active TB, and the physicians 
decide from the X-rays which patients must be summoned for further diagnostic 
work-up.  The result of each consultation is reported to the Reception Centre or to the 
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special Transit Centre for TB Treatment which is another central institution in the 
Oslo area.  If tuberculosis is diagnosed, the asylum seeker is kept at the latter centre 
for the treatment period.  Asylum seekers are also kept there while they still wait for 
their test results, or if a family member needs treatment.  Patients, who need hospital 
treatment while staying at the Transit Centre, may be admitted to any hospital in the 
Oslo area.  
 
Whenever an asylum seeker is relocated to a transit or asylum seekers centre, the 
health and other relevant information is normally sent to the public health nurse who 
is in charge of that centre.  In case an asylum seeker leaves the National Reception 
Centre and moves directly to some private accommodation, the screening results are 
sent to the public health officer in that particular municipality.   
 
Follow-up of screening results  
According to the national guidelines, the local public health care (PHC) is responsible 
for assessing the TB screening results of all asylum seekers and to follow them up 
(23).  As a result of the assessment, a decision is made if there is a need for further 
examinations or referral to specialist care, or that no more follow-up is needed.  
Suspected cases can thus be referred to specialist care directly from the National 
Reception centre or from PHC. 
 
Asylum seekers may move from the National Reception Centre to a new location in 
several ways (Table 1 & Figure 4).  As a first possibility, they may move to the 
Transit Centre for TB Treatment.  Second, they may be directed to one of the four 
transit centres that are located around Oslo.  This is an alternative for asylum seekers 
who have not yet been interviewed by the police, or have arrived through another 
Schengen country and await deportation, or some other decision.  Third, as is most 
often the case, the asylum seekers move to asylum seekers centres that are located in 
different parts of the country (Figure 4).  Finally, some few may move directly from 
the National Reception Centre to private accommodation.   
 
After staying in a transit centre or asylum seeker centre for a shorter or longer period 
of time, many may move again, i.e. either to another asylum seeker centre or to 
private accommodation in a municipality.  Some may leave the country.   
 21
 
 
Table 1. Type and characteristics of institutions for asylum seekers in Norway  
 
Institutions (total 
numbers) 
Functions Health care 
level 
Staff Source of 
information for the 
study 
 
National 
Reception Centre 
(1) 
 
Short term. 
All asylum seekers (AS) who 
arrive to Norway.  Screening with 
chest x-ray and Mantoux.  
 
Primary health 
care (PHC) paid 
for by national 
government.  
 
PHC officer or 
nurse 
 
Information from the 
computer system of 
the National 
Reception Centre. 
 
TB Treatment 
Transit Centre (1) 
 
Short or long term. Treatment of 
patients with active TB, or 
potential patients waiting for 
consultation or examination 
results.  Family members are 
included. 
 
PHC paid for by 
national 
government 
 
PHC officer or 
nurse 
 
Filled in PHC 
registration forms 
 
Central TB Clinic 
(1)   
 
Out patient. 
AS referred directly from the 
National Reception Centre or 
from other health care levels. 
Focus is on active TB.  
 
Hospital based 
specialist health 
care. 
 
Specialists in 
pulmonary 
medicine 
 
Returned specialist 
registration form 
 
Transit centre (4) 
 
Short term stay. AS who wait for 
an interview by police or for 
being deported.   
 
PHC paid for by 
national 
government 
 
PHC officer or 
nurse 
 
Returned PHC 
registration forms 
 
Asylum seeker 
centre (ca 100 
when study 
started,  Jan 2005) 
 
Longer stay.  AS stay till they get 
a permanent residency or are 
deported.   
 
Municipal 
authorities 
directly 
responsible for 
health care.   
 
PHC officer or 
nurse 
 
Returned PHC 
registration forms 
 
Specialist health 
care 
 
Out patient. 
Examine and treat AS for TB 
after referral from primary health 
care 
 
Hospital based 
specialist care. 
 
Hospital 
specialists in 
pulmonary or 
internal medicine 
 
Returned specialist 
registration form 
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Each time the asylum seeker moves, the public health officer is expected to forward 
the tuberculosis screening results to his or her colleague in the next municipality. 
 
1.6: Screening tests 
Chest X-ray 
The most common screening procedure for detecting tuberculosis disease is a frontal 
chest X-ray that was developed in the late 1930s and early 1940s (19).  Thus, mass 
examination in Norway was first introduced in 1940 (19).  X-rays are normally used 
as a first screening procedure to select persons for further examinations.  Positive X-
ray findings can not be used as the only diagnostic criterion (27).   
 
The value of an X-ray result depends not only on the quality of the film and the 
uptakes, but also on how the film is read.  Screening programmes do not normally 
include lateral uptakes which implies that some pathology may be overlooked (28).  
In general, intrabronchial disease does not show well on an X-ray (29).  Several 
studies have documented that there is a problem with within as well as between reader 
variability.  Further, while under-reading has been a frequently noted problem, over-
reading has been much less so (27, 30, 31).  The quality and size of the films, the 
experience of the reader, and the complexity of the reading code may all affect these 
factors (27, 28, 30, 31). 
 
Another problem with chest X-ray screening is related to the tuberculosis disease. 
Naturally, chest X-rays can only detect pulmonary pathology while the disease can 
affect all body organs.  Thus, a patient can be seriously ill of tuberculosis, but have no 
signs of pulmonary pathology.  Many different pulmonary diseases, previous and 
current, can give pathological changes on X-ray, and inversely, there is no X-ray 
findings that are exclusively found in tuberculosis (27).  Finally, X-ray can not 
differentiate between active and inactive TB except through repeated examinations 
(31).   
 
There is an ongoing concern if and to what extent patients with pulmonary TB can 
have a normal X-ray.  Thus, X-rays of culture positive cases have been used in several 
studies to find the proportion of negative X-rays and factors that are associated with a 
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negative finding.  The proportion of X-ray negative TB cases has varied between 0.5 
and 9 % and with the highest proportions in studies with the highest number of HIV 
positive cases (29, 32, 33).  In HIV positive tuberculosis patients, with decreasing 
CD4-cell counts an increasing number of atypical findings have been observed (34, 
35). 
 
In a review that evaluated the cost-effectiveness of TB screening, the sensitivity of a 
chest X-ray was found to lie between 59 and 82% and the specificity between 52 and 
63% for pulmonary TB (36).  However, different diagnostic criteria were used in 
these studies, and they were done in populations with a different prevalence of both 
tuberculosis and other lung diseases. 
 
Tuberculin skin tests 
A tuberculin skin tests (TST) has been used for almost a hundred years with different 
application forms like Mantoux, Heaf test and Pirquet.  In Norway the Pirquet method 
with Old Tuberculin was used until 2004 when the tuberculosis control programme 
changed to the Mantoux test (11).  The protein purified derivative (PPD) that is used, 
have several different standard concentrations and volumes.  PPD consist of a mixture 
of antigens, with a culture filtrate of M. tuberculosis, which induces a delayed cell 
mediated immune reaction.  In most use now is the Mantoux test, where PPD is 
injected intradermally and can be read as an induration of the skin after 48-72 hours 
(37).  TST measures a mycobacteria specific T-cell response and can not distinguish 
between tuberculosis infection and disease.  
 
The sensitivity, and even more the specificity of TST varies widely depending on the 
population the test is applied to (38).  The BCG vaccine and most atypical 
mycobacteria give a cross reaction with TST (37).  In two reviews where TST was 
compared to interferon- release assays (IGRAs), TST had a specificity of 56 and 
57% in BCG vaccinated populations, 97 and 98% in unvaccinated populations and 
66% in a mixed population (39, 40).  The sensitivity was 71 and 77% in two 
published reviews.  
  
In general the TST reaction is reduced in immune-compromised persons, and may 
increasingly wane with time after infection with TB (37, 41).  Further, the TST does 
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not revert after treatment for active or latent TB.  Repeated tests can boost the 
reaction, in particular if the person is BCG vaccinated or has previously been infected 
(37, 39).  
 
TST results are measured on a continuous scale and different cut-off values are used 
for different risk groups (38).  Accordingly, the predictive values will depend on both 
the risk of the group under study, and the cut-off values used (37, 38).  
 
Interferon gamma release assays  
Because of the limitations of the TST, a more specific test to diagnose latent TB and 
predict later development of active TB has been wanted.  Two new blood tests are 
available commercially.  They are different versions of QuantiFERON-TB Gold, and 
T-SPOT.TB which was formerly named ELISPOT.  Both are based on the cellular 
immune response and measure blood T-cell interferon gamma (IFN-) response to 
antigen stimulation, QFT measures the IFN- by an ELISA technique (39).  The two 
M. tuberculosis specific antigens ESAT-6 and CFP-10 have previously been used, but 
some current versions of the test have added another antigen, named TB7. IFN- is 
measured on a continuous scale, but a certain cut-off level between a positive or 
negative test is decided.  When the IFN- production after unspecified antigen 
stimulation is reduced, the positive control fails and the test result is indeterminate 
(42).  This could happen e.g. in HIV infected persons with low CD4 cell counts. 
 
Neither TST nor IGRAs can differentiate between active and latent TB and there is no 
microbiological method to diagnose latent tuberculosis.  Thus, in most studies a 
culture positive TB has been used as a reference for the sensitivity of various tests.  At 
the same time, the specificity has been assessed in populations where the probability 
of tuberculosis disease is quite low.  In two reviews, a pooled specificity of 97.5 and 
98% was found, whereas the pooled sensitivity in both was 76% (39, 40).  
Concordance with IGRAs and TST at different cut-off levels have been used to 
evaluate the tests (39, 43).  In contacts of cases of pulmonary TB, correlation between 
the degree of exposure and a positive test has been compared for TST and the IGRAs.  
However, for both these methods the results have been diverse (39, 44, 45).  Fewer 
studies where IGRA tests have been compared to TST have been performed in high 
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incidence countries, where the TST seemed to perform better than IGRAs and better 
than in low incidence countries (46).  
 
Only a few reports with a relatively short follow-up time have studied how IGRAs 
can positively or negatively predict later development of tuberculosis (44, 45, 47, 48).  
First, a German study with two years observation of contacts of active TB cases 
showed higher TB progression rates for a positive QFT than for a positive Mantoux 
(44).  Further, two Japanese studies of contact tracing among students found no cases 
of active TB among QFT negative students after 3 to 3.5 years of observation (45, 
47).  And third, an Austrian study of HIV infected individuals, showed that only those 
with a positive QFT test developed active TB in the follow-up period (48).  In 
contrast, a study from Gambia with ELISPOT showed that equal proportions of 
household contacts with positive ELISPOT and positive TST progressed to active TB 
in a two-year follow-up (49).  
 
The predictive properties of the new tests are still uncertain and there are many other 
questions and concerns that must be resolved, e.g. the repeatability, stability, boosting, 
waning, and their use in immune compromised patients (39, 49-55). However, the 
main benefit of the IGRA tests compared to TST is that the former are not affected by 
BCG vaccination and only to a limited degree by atypical mycobacteria (56).  Another 
advantage of the blood test is that the patient needs to see the health care provider just 
once. 
 
1.7: Risk factors for tuberculosis  
Risk factors for tuberculosis can be divided into two main groups: risk factors for 
being infected and risk factors for being ill.  Some risk factors are related to both 
groups, and may be difficult to separate.  The overall most important risk factor is 
poverty (57).  
  
Risk for infection 
Risk factors for infection have mainly been investigated through population based 
cross sectional studies, sometimes with a regular follow-up, or through contact 
tracing.  Until recently only tuberculin tests were used to measure infection 
 26 
prevalence, but now studies with interferon gamma release assays have been 
performed as well (43).  It is necessary to inhale M. tuberculosis to become infected 
which in turn depends on circumstances that increase the risk of inhalation.  Living 
close to a contagious patient in small rooms with no ventilation will increase the 
possibility of being infected.  The same is the case for poor living conditions, crowded 
households, and poverty in general (57, 58). 
 
Risk factors for disease  
Risk factors for disease include both risks for primary and reactivated (post primary) 
TB.  Such risk factors have mainly been investigated through prevalence studies, and 
case control or retrospective studies after the TB cases were diagnosed (59-61).  In 
addition ecological studies (57) and use of population based registers have been used 
(58).  Individual factors and diseases that affect immunity, like HIV infection (58), 
malnutrition, low body mass index (62) and immunosuppressive treatment are 
important for development of disease.  Recent infection (60), former untreated active 
tuberculosis (59), age (63) and life style factors like alcohol and tobacco use are other 
known risk factors (64, 65).  Several studies show an increased risk for males and 
some have shown an increased risk for unmarried people (61).  
 
Before starting treatment for latent tuberculosis the individual risk for reactivation 
must always be assessed.  The probability that a positive test for latent TB represent 
an infection with M. tuberculosis may vary between different risk groups (38).  
Further, different cut-off values for TST have been used in different studies (38, 39).  
In addition, in some populations a high degree of re-infection takes place (66).  
Altogether, these factors could probably explain why the assessed risk for reactivation 
of active TB varies greatly in different studies (67, 68).  
 
Recent infection, and the high probability that a positive test for latent TB represent 
an infection with M. tuberculosis, has been shown among contacts to cases of active 
tuberculosis.  Infected contacts have a 2-5% risk of developing TB within the first two 
years (69).  The life-time risk was 10-15%, i.e. if the contacts in question were 
infected at a relatively young age and included reactivation at old age (69).  In 
immune compromised patients the risk for reactivation of TB infection was found to 
be up to 5-15% per year (69).  Two Canadian studies of different risk groups showed 
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quite diverse results with high rates in household contacts increasing with TST size in 
one study, and a considerably lower risk in TST positive screened subjects without 
any known risk factors in the other (67, 68). 
 
In a “State of the art” paper on treatment for latent TB all comparisons were made 
with an infected person with no known risk factors (70).  For patients with AIDS, the 
risk for reactivation was increased up to 110-170 times.  Correspondingly, the 
increase for patients with a recent TB infection was 15 times.  The risk for 
reactivation was 1.5-5 times for persons treated with steroids, diabetes mellitus, 
underweight, who smoked, and were young when they were infected.  Individuals 
with X-ray findings that suggested an inactive TB in combination with no report of 
any adequate treatment, also had an increased risk for reactivation compared to other 
similar groups (70).  
 
Refugees as a particular risk group 
Several studies suggest that refugees have a high risk for TB disease following 
immigration to Western countries, and that the increased risk lasts for years (71, 72).  
High incidence rates for TB in refugees from Somalia and ex-Yugoslavia were found 
in a Dutch study (71).  An Australian cohort of mainly Southeast Asian refugees with 
negative X-rays and a positive TST that was followed for an average of ten years after 
arrival, showed that the incidence rates increased with increasing TST size and 
remained high for several years (72).  One study from USA found that the risk for TB 
among refugees was twice as high as for other immigrants, while another US study 
showed that refugees from Bosnia Herzegovina had a three times higher TB rate than 
the registered rate in their home country (73, 74).  Poor living conditions or nutrition 
before immigration, e.g. as a result of war or living conditions during or after 
immigration may explain some of the reasons for this increased risk in refugees (75, 
76).  
 
1.8: Latent tuberculosis  
Definitions of latent tuberculosis 
The TBNET (European network for clinically oriented TB research) consensus 
statement defined latency as a state of persistent mycobacteria-specific T-cell 
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responses, in the absence of clinical evidence of tuberculosis (69).  However, a 
positive TST or a positive IGRA test in absence of active disease is commonly used as 
a working definition of latent tuberculosis (40). 
 
Pathology 
The traditional view has been that an infection with M. tuberculosis leads either to 
primary TB, life-long latent TB, or latent TB developing to reactivation (post 
primary) TB (77).  Reinfection has also been documented to cause TB (78).  The main 
discussions have been about latent TB, but also about reactivation and reinfection (69, 
77). 
 
The relationship between infection, latent TB and reactivation has been based on the 
observations that old people who had been infected in their youth and were without 
any possibility for a recent infection, nevertheless became ill.  It has also been based 
on the positive association between a positive TST and later development of active 
TB (72, 79).  Another fact that has supported this theory, is that treating persons with 
a positive TST reduces the risk for later development of active TB (80).  Some new 
studies with genetic typing of bacteria have detected the same bacteria in TB among 
contacts of cases up to 33 years after the primary case was detected (81).   
 
Does everybody who is infected have viable bacteria?  Must the bacteria replicate in 
order to stimulate an ongoing immune response, or can they be dormant for a long 
period?  How and where can the bacteria survive?  Why is treatment effective when 
isoniazid is not effective against dormant bacteria but only against bacteria which are 
replicating?  These are some of the questions about latency, and not all of them have 
as yet a satisfactory answer.  Several old autopsy studies cultivated bacteria both from 
granuloma and from lung tissue elsewhere.  Although these studies have been 
criticised for their methodology, their results still indicate that persons with latent 
tuberculosis often have viable bacteria (77, 82).  Within a granuloma it seems that 
some bacteria of the same strain of M. tuberculosis replicate slowly while others do 
not replicate at all (69, 77, 82).   
 
Young and colleagues suggested a new model to explain bacterial load and immune 
response (77).  The response to a TB infection, thus, includes a spectrum of events; 
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i.e. from elimination of bacteria without priming an immune response to fully 
developed clinical disease (Figure 5).   
 
In some cases of previously treated TB, molecular studies have shown that a new 
occurrence of TB was actually a reinfection with a new strain of a different genotype 
and not reactivation of the former M.tuberculosis strains (78, 83).  TB disease in cases 
of reinfection may be explained as a strong reaction from a previously primed 
immune system (69, 77). 
 
There are still many unresolved questions about latency and reactivation.  However, it 
seems that M. tuberculosis can persist and lead to active tuberculosis after a shorter or 
longer period of time (69, 77, 78, 82).   
 
 
 
 
 
 
 
 
 
 
Figure 5. Theory on mechanisms of tuberculosis 
infection.  Reprinted with permission from Young DB et al 
(77) 
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Treatment of latent tuberculosis 
There are two different objectives for treating latent tuberculosis; the individual 
benefit of disease prevention and that of society and public health.  European 
recommendations for tuberculosis control and elimination in low incidence countries 
was introduced by a working group in 2002 (84).  According to this report, reducing 
the prevalence of tuberculosis infection is appropriate when low incidence countries 
approach the elimination phase (0.2-1 TB case/100 000 per year).  Thus, the report 
advised more extensive use of preventive therapy for latent tuberculosis (84). 
 
Before a decision is made about treatment for the individual patient, it is important to 
consider the probability of a true positive test, the risk for reactivation of disease, 
effect of treatment, risk for side-effects, and the likeliness that the treatment will be 
completed.  The choice of treatment regimens is a balance between documented 
efficacy, probability of side effects from drugs, and the convenience of the patient.  A 
large clinical trial with isoniazid detected a 93% reduction of TB cases in “completer-
compliers” of 12 months treatment and 69% in 6 months treatment (80).  However, in 
the longer treatment regimens default rates and side effects increased compared to 
shorter regimens (80).  A Cochrane review on isoniazid intervention trials in HIV 
negative patients found a 60% reduced risk for TB in the treatment groups (85). 
Generally, in shorter regimens more patients complete a full course, and patients  
influence on choice of treatment also improves the adherence (86).  Regimens that 
contain rifampicin are shorter and show better compliance, but are clinically not so 
well documented.  However, in a meta-analysis a short-course therapy with rifampicin 
and isoniazid was compared with standard isoniazid therapy.  The authors concluded 
that both alternatives had the same efficacy, proportions of side effects, and mortality 
(87). 
 
Side effects, such as drug-induced hepatitis from isoniazid treatment, increase with 
age, and after 45 years the risk mostly outweighs the favourable effect in persons with 
long-standing infection, but not in persons with a recent one (69).  Active TB is an 
absolute contraindication, and must be excluded before treatment of latent TB is 
started.  For isoniazid treatment the relative contraindication is acute hepatitis, and for 
rifampicin simultaneous intake of protease inhibitors (69). 
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1.9: Previous studies of screening of asylum seekers in Norway 
Several epidemiological studies have been performed on immigrants in Norway (9, 
12, 43, 88).  In addition, there have been two follow-up studies of the X-ray results 
after screening of asylum seekers (89, 90).  Of the latter two, the first one was 
published in 1996 and showed that just 68% of asylum seekers with positive X-ray 
findings on arrival had been clinically examined when they were assessed three years 
later (89).  In the other, 11 of the 76 TB cases that were diagnosed within one year 
after arrival, had a positive X-ray on arrival, but still had not been clinically examined 
(90).    
An unpublished survey of information flow and follow-up of screening results of 
asylum seekers, conducted both in the primary and specialist health care, revealed 
several problems between the two levels of care.  That effort nevertheless gave some 
important background information for the present doctoral dissertation research. 
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2: Aims and objectives 
2.1: Overall aims 
The overall aim of the research was to assess the effectiveness and efficacy of 
detection, treatment, and follow-up of active and latent tuberculosis among asylum 
seekers to Norway.  The assessment included screening procedures at entry, the 
implementation of national guidelines at all levels of public health, and clinical 
follow-up of individual asylum seekers.  
 
 
2.2: Specific aims for the individual papers 
Paper 1: The aim was to assess to what extent the national regulations and guidelines 
for screening, treatment, and follow-up of tuberculosis disease and infection among 
asylum seekers had been implemented at the primary and specialist health care levels 
in Norway.  
 
Paper 2: The aim was to assess the follow-up of the TB screening results of asylum 
seekers with emphasis on demographics, screening outcome, how follow-up was 
organised, and how this influenced treatment for latent tuberculosis.  Another aim was 
to study reasons why asylum seekers were not examined and identify factors that 
influenced follow-up.  
 
Paper 3: The aim of the paper was to assess the effectiveness of diagnosing active TB 
by the tuberculosis entry screening programme of a cohort of asylum seekers.  We 
compared cases of active TB that were diagnosed by the screening programme with 
cases detected outside the programme.  We further aimed to characterize all new cases 
with active tuberculosis. 
 
Paper 4: The paper aimed to compare the predictive properties of QuantiFERON TB 
Gold (QFT) with the Mantoux test as an entry screening tool to identify individuals 
with concurrent or later tuberculosis disease. 
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3: Material and Methods 
  
3.1: Study population 
The study population is asylum seekers and almost every asylum seeker who arrives 
in Norway is sent to the National Reception Centre, Tanum, outside Oslo.   
 
Inclusion into the follow-up study group  
All asylum seekers above the age of 18 who arrived at the National Reception Centre 
from January 2005 till June 2006 were eligible for inclusion.  They were included if 
they had one or more of the following characteristics: a Mantoux test of 6 mm or 
more, a chest X-ray with calcifications, pleural pathology or parenchymal pathology, 
or a positive immune globulin release assay test, QuantiFERON®TBGold.  Asylum 
seekers who could not be followed up were excluded if information at the Reception 
Centre disclosed that they had left the centre without any kind of address, already had 
left the country or been deported, or had died.  For these reasons 469 persons were 
excluded before and 56 after primary inclusion. 
 
Inclusion into the QFT study 
Asylum seekers above the age of 18 who arrived from September 2005 were further 
invited to participate in a separate substudy (QFT study) (43).  The aim of that study 
was to enrol 1000 persons, a measure that was reached in June 2006.  However, a 
conclusive QFT test result was available for only 912 participants.  The reason for this 
was partly of a technical nature, that a number of participants later withdrew their 
consent, or that their TST result was missing (43).  When the study identification 
number of these 912 individuals was matched with the list of names as well as with 
the cohort available for follow-up (see “total cohort”, page 39), another 89 subjects 
were lost.  Accordingly, 823 asylum seekers were matched with the National 
Tuberculosis Register and could be included in the analysis (Paper 4).  All TB cases 
independent of time of diagnosis were analysed. 
 
3.2: Test procedures on arrival to Norway 
Chest X-ray 
In general radiographers at the Reception Centre took the chest X-rays.  In emergency 
cases or if necessary for other reasons, nurses who were available, did.  During the 
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early phases of the study period the X-ray equipment used was Siemens Thoramat 100 
mm film with manual development.  This equipment was replaced by the digital 
system Axiom Aristos TX from August 2005.  Until the middle of January 2006, the 
chest X-rays were read at the Reception Centre by two independent readers, one 
specialist in pulmonary medicine and one radiologist.  In case of disagreement, the 
two discussed the X-ray together and the first reader made the decision.  After that 
time the chest X-rays were sent digitally to Ullevål University Hospital where they 
were also read by two independent readers.  Again they were a radiologist and a 
specialist in pulmonary medicine.  Only X-ray findings that required a clinical follow-
up at the Central TB Clinic at Ullevål University hospital were reported back to the 
Reception Centre.  
 
One of the physicians who had read the X-rays at the Reception Centre, re-read the X-
rays of the persons who were included in the QFT study.  This was done in order to 
make the reports after mid-January 2006 comparable to the reports from before that 
time. 
 
The written results of the X-ray examinations were recoded for the present study and 
separate codes were given for calcifications in lung, hilus or mediastinum, pleural 
pathology, and for parenchymal pathology.  The latter included previous and current 
TB. 
 
The Mantoux test 
We employed the PPD; PPD: RT 23, 2TU (SSI, Copenhagen) for the present study.  
Four experienced nurses applied and read the test.  A test was considered positive if 
the induration was  6mm after 72 hours.  If the induration was very large, showed 
adverse reaction or was hard to read, two persons read the test and agreed about the 
result.  
 
IFN- release assay  
The blood samples were drawn at the National Reception Centre and analysed at the 
National Institute for Public Health.  QuantiFERON®-TBGold in tube test (Cellestis 
Ltd, Carnegie, Victoria, Australia) was used and incubated, processed and stored 
according to the manufacturer’s recommendation advice.  A positive test was defined 
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as  0.35 IU IFN- /ml.  Positive tests were confirmed by a reanalysis.  The result was 
reported as non-conclusive when the confirmatory test was negative (43).  
 
3.3: Data collection 
 
The National Reception Centre 
At the National Reception Centre information about demographics, screening results, 
referrals, and information about the relocation of asylum seekers were filed in a 
computerized system.  In order to identify the study participants and study 
information, the operator for this computer system searched the files for certain 
words, groups of words, and dates (Appendix 1).  If important study information was 
missing, e.g Mantoux results, the data files were searched manually in case the 
information could have been registered under a different heading.  
 
Follow- up registration  
To collect information from different parts of the health care system, study forms 
were sent to officials of primary (community) and specialist (hospital) health care, 
respectively.  The forms collected information about demographics, registration and 
flow of information, previous medical history, TB risk factors, symptoms and results 
of clinical examinations, plans for follow-up or referrals, and relocation of study 
participants.  Community health officials were asked if the asylum seeker had been 
examined or assessed, and we wanted to know the professional level of the examiner. 
Further, we asked if and why the asylum seeker had been referred to specialist health 
care.  If no referral had taken place, we also asked for the reason why.  In case an 
asylum seeker had been relocated to another municipality, a primary health care form 
was sent there (Figure 4 & Figure 6). 
 
If a study participant had been referred to a specialist or hospital for further diagnostic 
work-up, a separate registration form was sent there.  Personnel at the specialist health 
care level were asked more in detail about diagnosis, treatment indications, and 
treatment for latent tuberculosis for each asylum seeker who had been referred to 
them.  Whenever information held at the National Reception Centre suggested that a 
patient had been referred directly to the Central TB Clinic at Ullevål University 
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Hospital, they received the same specialist form.  A specialist form was also sent to 
that clinic for all cases who were registered with a positive chest X-ray finding on the 
initial screening. 
 
In order to increase the response rate certain measures were taken.  Thus, information 
about the study was given at meetings, and through the information channels of the 
National Health Institute and the Norwegian Chest Association.  The PhD candidate 
personally visited all four transit centres and sent letters or made phone calls to 
remind health care personnel to return the study forms.  
 
The data collection took place from February to December 2007.  The time from the 
asylum seekers arrived in the country till data collection was completed ranged from 9 
to 35 months and took a median of 18 months. 
 
The Norwegian National Tuberculosis Register  
The register contains information about all patients diagnosed with active 
tuberculosis.  The registration includes date of diagnosis, results of bacteriological 
culture results, localization of disease, and treatment given.  In addition, the register 
has information on everyone who has started treatment of latent tuberculosis.  The 
register is regularly updated against the national register of drugs prescribed for 
tuberculosis. 
  
Name and birth dates from all included study participants (n=2237) were matched 
with the Norwegian National Tuberculosis Register.  The first match was done on 
December 31st, 2006 (Paper1), and the second one by the end of May 2008 (Papers 2-
4).  The matching was done by specially assigned personnel at the National TB 
Register.  A separate match was done for the subgroup of participants who had a 
negative QFT result (Paper 4). 
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 Figure 6. Flow of study forms 
 
When an asylum seeker left the National Reception Centre, a primary care registration 
form was sent to the public health officials in the municipality where (s)he had moved.  If 
we received information that the asylum seeker had been referred to specialist health care 
or we were informed that the asylum seeker had been examined at the Central TB Clinic, a 
specialist registration form was sent there. 
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3.4: Data registration and analysis 
Scanning and quality check  
Study registration forms were scanned and entered into SPSS for Windows, version 
15 (Chicago, IL, USA) (Paper1 and 2) and version 16 (Paper 3 and 4).  About 15-20% 
of the forms were controlled for errors in the scanning process.  We found such errors 
on 0.5-1% of the forms.  Comments and administrative information were coded 
manually and entered to the same data file. 
 
Data analysis 
In papers 1-3 frequencies were analyzed with proportions and 95% confidence 
intervals (CI).  Groups with certain characteristics were compared and considered 
significantly different if the confidence intervals were not overlapping. 
Logistic regression was employed in papers 2 and 3.  Variables in the univariate 
analysis that changed the odds ratio (OR) of the other variables with 0.2 or more were 
entered into the multivariable analysis.  Most variables were dichotomized whereas 
variables with more than two levels were categorised.  All models were checked for 
correlations and interactions. 
   
In paper 1 descriptive statistics was used as outlined above.  Groups were compared 
on demographics, while positive X-rays were also compared using separate X-ray 
codes. 
 
In paper 2 the asylum seekers at each follow-up level (Figure 7) were compared with 
descriptive statistics as described.  The most critical stages for the referral process 
were analyzed with logistic regression.  Those critical stages were: patients seen in 
community health care (yes/no), referred to specialist (yes/no), seen by specialists 
(yes/no), and started treatment for latent TB (yes/no).  Variables with more than two 
levels were categorised with the youngest age group as reference for age and Europe 
as the reference for continent.  
 
In paper 3 the study group and the TB cases were described by proportions and 95% 
CI.  The primary outcome was diagnosed with active tuberculosis (yes/no) that was 
analysed with logistic regression.  Again, age was categorised with the youngest age 
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group as reference, whereas Somalian origin (yes/no) was added as a separate 
predictor variable.  The low number of cases limited the number of regressors that 
could be included in the multivariable analysis.  The following were included; country 
of origin, gender, and either Mantoux  10mm or Mantoux  15mm, or a positive X-
ray.  
 
An important outcome was if the tuberculosis case had been detected by the screening 
programme or not.  This outcome was studied by univariate logistic regression.  
Additional regressors were a pulmonary vs extra-pulmonary TB diagnosis and a 
positive vs negative bacteriological culture.  
 
In paper 4 we compared the positive (PPV) and negative predictive properties (NPV) 
of the QFT and the Mantoux test used to identify current or later tuberculosis disease 
(91).  We also estimated 95% CI for both PPV and NPV.  Separate estimates for PPV 
were made with and without the exclusion of study participants who were treated for 
latent TB, as shown in paper 4. 
 
3.5: Ethics 
We did not ask for informed consent from the asylum seekers.  The reason was that 
we estimated that about half of the study participants would have left the country 
before the study onset and that those still residing in Norway would be difficult to 
trace.  Our arguments were accepted by the Regional Committee for Medical 
Research Ethics who gave their permission.  The Norwegian Data Inspectorate, The 
Directorate for Health and Social Affairs, and The Ministry of Labour and Social 
Inclusion all gave their permission.  The Research committee at Ullevål University 
Hospital gave their permission to collect information from the Central TB Clinic.  The 
Directorate for Health later gave us a separate permission to match study participants 
who had a negative QFT test with the National Tuberculosis Register. 
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Response from specialist
N=220
Referrals to specialist
N=236
Seen by specialist
N=169
Seen in PHC2
N=675
Response from PHC2
N=1625
Study group
N=2237
Central TB Clinic
N=185
No response
N=612
Not in contact
with
PHC2 N=919
Seen, but
not referred to 
specialist N=470
No response
from specialist
N=16
Not seen by
specialist N=51
N=205
Directly
Referred N=31
Total cohort
Eligible for inclusion
N=4643
Positive inclusion criteria
N=2293
Arrivals N=5112
untraceable1
N=56
untraceable1
N=469
 
 
 
 
Figure 7. Study population and follow-up (from Paper 2) 
1 Asylum seekers were untraceable if they left the country without a forwarding address, were deported or 
died before leaving the National Reception Centre.   
2 Primary (community) health care.  Bold letters indicate the critical stages of the referral process 
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4: Results 
4.1: Description of the separate sub-cohorts 
Total cohort characteristics 
From January 2005 till June 2006, 5638 asylum seekers arrived in Norway, of whom 
5112 arrived at the National Reception Centre.  Because they were deported directly, 
disappeared, died or left behind no address when they left the Reception Centre, 469 
of the latter group were excluded.  Thus, 4643 were eligible for the follow-up study 
(Table 2 & Fig 7).  Among them, 3333 (73%) persons were 18-34 years old, 3222 
(69%) were males, and 1883 (41%) were married.  Nine hundred and sixteen (20%) 
persons came from Europe (exclusively from Eastern Europe), 1724 (37%) were 
Africans, while1819 (39%) came from Asia.  The five most frequent countries of 
origin were Iraq (15%), Somalia (15%), Russia (8.2%), Afghanistan (7.2%), and 
Serbia and Montenegro (6.6%).  Positive X-rays were found in 323 persons (including 
the ones that were re-read), and 2127 had a Mantoux test  6 mm.   
 
Study cohort characteristics 
Altogether 2293 persons had one or more of the inclusion criteria, but 56 of them 
were excluded because they left without an address or were deported.  Thus, 2237 
persons were included in the study cohort (Figure 7 & Table 2).  Among those, 1447 
(65%) were 18-34 years old, 1563 (70%) were males and 1034 (46%) were married.  
Altogether 390 (17%) came from Eastern Europe, 1007 (45%) were Africans, and 774 
(35%) came from Asia.  Again, the five most frequent countries of origin were 
Somalia (457; 20%), Iraq (224; 10%), Russia (182; 8.1%), Afghanistan (166; 7.4%). 
and Serbia and Montenegro (149; 6.7%). 
  
Positive X-rays were found in 314 (14%) persons (including the X-rays that were re-
read), 1440 had a Mantoux from 6 to 14 mm, 638 had a Mantoux  15 mm (Table 2). 
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Table 2. Total cohort and study cohort described by demographics and screening results 
with % and 95% CI 
 
 
 
Groups Total cohort 
N=4643 (%) 
(95% CI) 
Study cohort 
N=2237 (%) 
(95% CI) 
Study cohort: 
Mantoux 6-
14mm 
N=1440 (%) 
(95% CI) 
Study cohort: 
Mantoux  
15mm, 
N= 638 (%) 
(95% CI) 
Age groups 18-34 years 3333 (72%) (70-73%) 
1447 (65%) 
(63-67%) 
984 (68%) 
(66-71%) 
358 (56%) 
(52-60) 
 35-49 years 1103 (24%) (23-25%) 
656 (29%) 
(27-31%) 
394 (27%) 
(25-30%) 
224 (35%) 
(31-39%) 
 >50 years 207 (4.5%) (4-5%) 
134 (6%) 
(5-7%) 
62 (4%) 
(3-5%) 
56 (8.8%) 
(7-11%) 
Gender Males 3222 (69%) (68-71%) 
1563 (70%) 
(68-72%) 
1067 (74%) 
(72-76%) 
375 (59%) 
(55-63%) 
 Females 1421 (31%) (29-32%) 
674 (30%) 
(28-32%) 
373 (26%) 
(24-28%) 
263 (41%) 
(37-45%) 
Marital status Married 1883 (41%) (39-42%) 
1034 (46%) 
(44-48%) 
656 (46%) 
(43-48%) 
310 (49%) 
(45-52%) 
 Not married 2769 (60%) (58-61%) 
1203 (54%) 
(52-56%) 
784 (54%) 
(52-57%) 
328 (51%) 
(48-55%) 
Continent of 
origin Europe 
916 (20%) 
(19-21%) 
390 (17%) 
(16-19%) 
244 (17%) 
(15-19%) 
127 (20%) 
(17-23%) 
 Africa 1724 (37%) (36-39%) 
1007 (45%) 
(43-47%) 
609 (42%) 
(40-45%) 
347 (54%) 
(51-58%) 
 Asia 1819 (39%) (38-41%) 
774 (35%) 
(33-37%) 
541 (38%) 
(35-40%) 
154 (24%) 
(21-27%) 
 South America 15 (0.3%) (0-0%) 
2 (0.0%) 
(0.0-0.0%) 
- 
 - 
 Stateless 169 (3.6%) (3-4%) 
64 (2.9%) 
(2-4%) 
45 (3%) 
(2-4%) 
10 (1.6%) 
(1-3%) 
Mantoux test <6 mm 2399 (52%) (50-53%) 
146 (6.5%) 
(6-8%) 
- 
 - 
 6-9 mm 687 (15%) (14-16%) 
680 (30%) 
(28-32%) 
680 (47%) 
(45-50%) - 
 10-14 mm 777 (17%) (16-18%) 
760 (34%) 
(32-36%) 
760 (53%) 
(50-55%) - 
  15 mm 663 (14%) (13-15%) 
637 (28%) 
(27-30%) - - 
Positive x-ray 
code  
323 (7%) 
(6-8%) 
314 (14%) 
(13-15%) 
77 (16%) 
(13-20%) 
70 (11%) 
(9-13%) 
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The QFT study subgroup  
Of the 823 persons who were included in the QFT substudy, 246 (30%) of the 
remainders had a positive QFT test and were included in the follow-up study (cf. page 
31).  They were compared with the 577 asylum seekers (70%) who had a negative 
QFT test (Paper 4). 
 
Twenty-seven of the 246 participants with a positive QFT test (11%) had this as the 
only criterion for inclusion in the study cohort. 
 
4.2: Results of the individual papers 
Paper 1: Tuberculosis screening and follow-up of asylum seekers in Norway: a 
cohort study 
Of the 4643 persons in the cohort, 97.5% had a valid Mantoux test.  By end 2007 the 
primary public health services had assessed 758 (34%) of the included 2237 study 
participants.  Among the 1326 persons with negative X-rays and a Mantoux test 
between 6 and 14, 372 (28%) had been seen in PHC.  Overall, the assessment took 
place a median of 9 weeks after arrival in the country (range 0-124).  
 
Altogether 328 persons were seen by a specialist.  However, some 13 of them were 
seen both at the Central TB Clinic and by a different internist following a referral 
from PHC.  Of the 314 persons who had a positive X-ray, 194 (64%) had seen an 
internist.  Significantly more persons with parenchymal X-ray findings were seen 
compared to those with other X-ray pathology.  Among 568 persons with a Mantoux 
 15 but negative X-rays, 86 (16%) were seen by an internist.  The median time from 
arrival in the country till the patients were seen by an internist was 25 weeks (range 0-
14). 
 
In a match with the National TB Register on 31st December 2006, 23 cases of active 
TB and 11 cases who had started treatment for latent TB were identified.  These 
figures have later been updated by May 2008. 
 44 
Paper 2: Screening and treatment of latent tuberculosis in a cohort of asylum 
seekers in Norway 
The study was based on the same 2237 asylum seekers who fulfilled the inclusion 
criteria (see “study cohort characteristics” above).  There was no association between 
the screening results on arrival and whether they were assessed in PHC or not.  
However, the degree of follow-up at the community level was associated to female 
gender, being married, and an African background.  There was also a positive 
association between referral to a specialist, and a positive X-ray and Mantoux  
15mm. 
 
By May 2008, 30 persons had started treatment for latent TB.  The median time after 
arrival was 17 months (range 3-36).  A Mantoux test  15mm on arrival was 
significantly associated to treatment.  
 
Internist classified 41% of their patients who had a Mantoux  15mm and a normal X-
ray as latent TB, and they concluded that there was an indication for treatment in 29% 
of them.  Among those with both positive X-rays and Mantoux  6mm, 40% were 
classified by internists as latent TB, and they concluded that there was a treatment 
indication for 25% of them.  Lack of a permanent visa among asylum seekers was a 
frequent reason for not starting treatment. 
 
The organisation of medical information handling of individual patients was clearly 
insufficient, and the same was management of information of follow-up and referrals. 
  
Paper 3: The role of entry screening in case finding of tuberculosis among 
asylum seekers in Norway 
Among the 2237 persons in the study cohort of asylum seekers, 28 cases of 
tuberculosis were diagnosed 0-27 months after arrival in Norway.  By the end of May 
2008, the reported data from the follow-up study were matched with the National 
Tuberculosis Register.  Fifteen cases were detected by the screening programme, 
which was defined as diagnosed within two months after their arrival.  Two cases 
were diagnosed between three and six months after arrival and were probably missed 
by the screening.  A positive X-ray on arrival was associated with detection.  Female 
gender and Somalian origin increased the risk for active TB.  Somalian background 
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was also positively associated to extra-pulmonary as compared to pulmonary TB.  
Seven of the cases that were diagnosed more than two months after arrival had not 
been subject to a proper evaluation and assessment of their screening results. 
 
Paper 4: Predictive values of QuantiFERON-TB Gold testing in screening for 
tuberculosis disease in asylum seekers 
Of 823 asylum seekers with a valid QFT result that was matched with the National TB 
Register, eight with a positive and one with a negative QFT were diagnosed with 
active TB.  This occurred after a maximum of 32 months of observation.  The positive 
predictive value (PPV) for QFT was 3.3%, and 2.3% for Mantoux  15mm, 
respectively.  A Mantoux  6mm in combination with a positive QFT test gave a PPV 
of 3.3%.  There were no significant differences in the predicting properties of QFT 
and the Mantoux test.  The negative predictive value (NPV) for Mantoux  6mm in 
combination with a negative QFT was 99.5%.  That combined test is thus equally as 
favourable as a Mantoux with cut-off of 15mm.  IFN- levels where not different in 
tuberculosis patients with a positive QFT compared with those with a positive QFT 
but no disease. 
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5: General discussion 
5.1: Study outcomes 
Asylum seekers and their characteristics 
The asylum seekers in our study came from countries where the TB incidences varied 
widely.  The five countries with largest proportion of asylum seekers have reported 
incidence rates  from 249/100 000 in Somalia to  56/100 000 in Iraq (92).  The total 
cohort had more males than females and was dominated by young adults.  The same 
have been found in similar studies (59, 72, 93, 94). 
 
Gender affected follow-up in PHC, and married women were more likely to be 
assessed (Paper 2).  May be they saw a health care provider more often in relation to 
pregnancy and problems with small children.  Females, particularly of Somalian 
origin, had an increased risk of active TB (Paper 3).  In studies from Western 
countries at the time when TB was more prevalent, females of fertile age had an 
increased TB risk compared to males of the same age (95).  The low numbers in the 
present study or inequalities in health seeking behaviours in their home countries may 
explain why our results differ from other studies from developing countries where 
males have a higher risk (95-97).  Several studies have shown that Somalian origin is 
strongly associated with TB (90, 98-100), as is the association with extra-pulmonary 
TB (98, 101).  It is noteworthy that estimates made by WHO show that the incidence 
rates (IR) inside Somalia are lower than those shown in studies among Somalians who 
live outside their country (90, 92, 100).  Still, there are some uncertainties related to 
these estimates.  For instance, the number of cases inside Somalia could be 
underestimated.  And it has been suggested that the IR among asylum 
seekers/refugees in general are higher than among other immigrants from the same 
countries (73).  At the same time, other studies have suggested that asylum seekers 
/refugees have higher rates than the IR in their home countries (74).  The latter is 
supported by the fact that before they reach their destination, asylum seekers and 
refugees often have been incarcerated.  Thus, they have lived in camps, some have 
been in prison and in general, their living conditions before and after arrival often 
have been quite poor.  As a consequence, a higher proportion may have acquired a 
recent infection, and experienced a general reduction in their immune defence.  
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Unfavourable living conditions during travel could also explain some of these 
findings (75). 
 
Asylum seekers may be more difficult to trace than other immigrants because they 
move more frequently, sometimes without reporting their whereabouts to the 
authorities.  Also, they may have been hesitant to reveal their identity for obvious 
reasons.  Their names and/or birth dates may be changed, either because of 
misunderstandings or by intention.  All of this will make them quite difficult to trace. 
 
Finally, if their residence application has been refused, many asylum seekers are 
deported out of the country.  Some of them may disappear from the official registers 
and either move abroad or choose to become illegal or undocumented immigrants.  
We do not know if or how many of them have tuberculosis and we do not know if any 
TB cases that occur among them are reported, either.  Still, a study of tuberculosis 
among undocumented migrants showed that this is a problem that needs attention 
(15). 
 
Organisational issues related to the location of asylum seekers and information 
flow 
During this study we mapped the movements of asylum seekers and the flow of health 
information.  We identified several pitfalls in how screening results were handled and 
often ended with lack of action.  The central authorities cover the cost of health care at 
the National Reception Centres and the four transit centres.  Further, the regional 
health authorities are responsible for all kinds of specialist health care, and the 
municipalities for primary health care.  Without doubt, we concluded that the system 
for follow-up of asylum seekers is both complex and complicated.  There are many 
steps, and there is a lack of coordination between the different levels of health care 
and between various authorities, e.g., the immigration and health authorities.  Asylum 
seekers are forced to move several times before they may settle down or are deported 
permanently.  Thus, the corresponding flow of health information was an 
overwhelming problem.  Frequently, individual health data was not kept or handled 
according to the legislation and documentation requirements, and many municipalities 
rarely retained information on asylum seekers that had moved on. 
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For 38% of asylum seekers with a positive X-ray finding on arrival, we have no 
information if a clinical examination had taken place.  And as shown in paper 3 we 
found three cases of active TB who were detected through screening and reported 
from hospitals in the Oslo area, but nevertheless went undetected by the follow-up 
study forms or files at the Reception Centre.  Thus, probably more cases had been 
seen by a specialist than we were able to confirm.  Still, many were not examined by a 
specialist in spite of a positive X-ray, which clearly is unacceptable.  Pre-immigration 
screening with X-rays is performed in Canada.  A follow-up study in immigrants with 
TB-related lung scarring, showed that less than half (45%) had been examined 
clinically after arrival (102).  It turned out that 45 % had no valid address and never 
received a referral letter in the first place.  This compares with the problems we had in 
tracing people and follow-up of X-ray results (102). 
 
As we followed the asylum seekers through the health care system, we observed that 
only 43% of those we received information about had been examined in PHC.  In 
addition, there was no association between screening results and the possibility of 
being examined (Paper 2).  The reasons could be lack of information about each 
individual asylum seeker.  Alternatively, it could also be due to lack of knowledge or 
interest, or to lack of priority of asylum seekers in the local communities.  We were 
unable to observe any traces of a common strategy in the various municipalities in 
relation to how they took responsibility for follow-up of TB screening results. 
 
The central health authorities have neither developed a documentation system for the 
outcome of the TB screening, i.e. in terms of a conclusive examination of individual 
asylum seekers, nor a quality assurance system.  That is deemed necessary, and as a 
minimum for asylum seekers with a positive X-ray.  
 
Screening tests 
X-rays 
Independent of the present research, the chest X-ray methods were changed during the 
study period.  From January till August 2005 X-rays were taken on miniature film, 
after which a digital system was introduced.  Further, a double reading of each X-ray 
was done at the Reception Centre.  Later, the digital films were read at the Ullevål 
University Hospital.  Thus, when the X-rays indicated that a follow-up was necessary, 
 49
the X-ray was classified as positive.  This way of classification reduced the number of 
cases recorded with a positive X-ray.  To get a more standardized classification for the 
entire QFT sub study, the X-rays of everyone who were included in that study after 
January 2006 were re-read by the physician who had read all the X-rays during 2005.  
This quality assurance procedure increased the number of positive X-rays from 288 to 
314 cases.  However, the extra positive X-rays from the re-reading were not reported 
to the health care authorities. 
 
We classified parenchymal findings, pleural findings, or mediastinum, lung or hilus 
calcifications as a positive or abnormal X-ray.  Thus, all the above 288 (Paper 2) cases 
should have been offered a diagnostic follow up by a specialist even if their individual 
risk for active TB varied.  Yet, those who had parenchymal pathology were more 
often seen by a specialist than those with other pathological findings.  We take that as 
a clear indication that some selection took place as regards the follow-up of asylum 
seekers with the highest risk. 
 
The results of X-rays used in screening have varied widely depending on the 
population examined, the different methods used for taking and reading them, and the 
definitions of a positive result.  Studies from The Netherlands, UK and Switzerland 
showed that 1.4-2.7% of immigrants had X-rays suggestive of TB (59, 94, 103).  But 
when all abnormal X-rays were included in the Swiss study, the proportion increased 
to 8.4% (103).  We found that 7% of our cohort had abnormal X-ray findings which 
are in accordance with the Swiss results. 
 
Mantoux test results  
According to our national recommendations and guidelines a Mantoux  15 mm 
should lead to a direct referral to specialist.  This was not the case however, as only 
16% with that test result had been seen by a specialist (Paper 1).  Still, once persons 
were seen in PHC and had a Mantoux  15 mm, there was a strong probability that 
they were referred to specialist for follow-up (Paper 2).  And once patients who were 
referred to a specialist, were actually seen and examined, there was also a positive 
association between a Mantoux  15 mm and treatment for latent TB (Paper 2).  We 
found a similar association between Mantoux  15 mm and active TB in Paper 3. 
  
 50 
The Mantoux test is one of the diagnostic tests for latent TB, but there is no 
conclusive agreement about how well it works.  A false positive test can be the result 
of BCG immunisation, in particular if it is given after infancy or repeated.  Another 
possibility is an infection with atypical mycobacteria (37).  On the other hand, an 
impaired immune system may give a false negative test result.  In our total cohort of 
4643 asylum seekers 71% had a BCG scar as compared to 75% in the study cohort.  
Most of the asylum seekers came from countries where the BCG vaccine is given to 
young children which would not affect the TST result.  However, in some Eastern 
European countries repeated vaccines are given which could influence the test results 
for these persons (104).  
 
QFT 
As a QFT test was not part of the screening programme when our study took place, 
we have not performed a detailed assessment of the use of it and the potential impact 
of a positive QFT on screening, follow-up and outcome. 
 
QFT was nevertheless taken on a subgroup of our cohort, even if it was part of 
another study (43).  The number of patients with active TB was low in this group, and 
we found no significant differences in the predictive properties between the QFT and 
the Mantoux test (Paper 4).  The main objective of the IGRA tests is to diagnose latent 
TB, but we may still be interested in how well later development of active TB is 
predicted.  Others have shown that persons with a negative QFT test do not develop 
active TB later on (45, 47, 48), and a contact tracing study found that PPV was higher 
for QFT than for Mantoux (44).  In contrast, a Gambian contact study that compared 
Mantoux and ELISPOT found no difference between them in predictive properties 
(49).  Studies that cover a longer follow-up time and various populations are needed 
to answer whether different IGRAs are as good as or better than Mantoux to predict 
active TB.  Because of our low numbers, our analysis included patients with active 
TB when they were tested as well as those who became ill later.  If we had restricted 
the analysis to patients who were diagnosed more than one month after arrival, no one 
with a negative QFT or a negative Mantoux would have been included.  On the other 
hand, that would have improved the negative predictive values for both QFT and 
Mantoux. 
 
 51
Screening outcomes 
A valid Mantoux test result was available for 97.5 % of the asylum seekers.  On the 
other hand, we were unable to ascertain exactly how many study participants that had 
a chest X-ray taken and read.  Thus, the implementation of the Mantoux test in the 
screening programme was quite good.  We conclude that a new or improved recording 
system for how often an X-ray is taken and the result reported back to the National 
Reception Centre is necessary.  
 
Within two months after arrival, 15 cases of active TB were detected which most 
likely was the result of the screening programme, and only two cases were detected 
between 3 and 6 months after arrival, probably missed by the screening (Paper 3).  
The majority of the TB cases had a positive X-ray on arrival and since the overall 
objectives of the screening programme were to diagnose pulmonary TB and minimize 
the risk of transmission, it seems that the intentions of the programme have been met.  
Because routines of a fast track examination of persons with a positive X-ray had 
already been established, this could have been expected.  The yield of screening 
programmes, i.e. the number of cases identified with a correct diagnosis, varies and 
depends both of the characteristics of the screened population and the validity of the 
individual programme.  Several studies of screening programmes reported TB 
prevalences that ranged from 0.1-0.5% (93, 94, 103, 105).  However, a review of 
screening of immigrants in Europe found a median yield of 0.18% (interquartile range 
0.10-0.35%) (106).  The yield of 0.7% in our selected high risk group was higher than 
the median, but still it compares well with the above studies. 
 
Thirty patients started treatment for latent TB, which took place 3-36 months after 
arrival (Paper 2).  This was fewer than expected and was initiated after quite a longer 
time than expected.  Even though other studies are not easily comparable with ours, 
they too, have shown that relatively few patients started treatment for latent TB as a 
result of screening (102, 107).  We see our unexpectedly low number as a 
combination of first, unacceptably few assessments in PHC, second, still fewer 
referrals to specialist, and finally, reluctance among specialists to start treatment.  
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Health care personnel 
We did not collect information among health care personnel about their knowledge 
and management of the screening programme.  However, from written and spoken 
responses and comments we received it seemed that the recommended management of 
screening results to some extent were both unknown and misunderstood.  In some 
cases lack of personnel or vacancies in PHC, or variation in the local practices were 
given as reasons for not completing and returning the forms, or for not handling the 
screening results according to guidelines. 
 
The response rate from the specialist health care providers was 93%.  We take that as 
an indication of professional interest in the issue.  However, we received no reply to 
our questions whether latent TB had been diagnosed, and whether treatment was 
found to be indicated in 28% and 23% of cases respectively.  Both community and 
specialist forms were filled in retrospectively using information the personnel had 
retrieved from their own health records.  Thus, information that was necessary for 
answering our questions could have been unavailable or inaccurate.   
 
None of the seven HIV positive patients that we detected, had received treatment for 
latent TB, and a positive X-ray was not associated with treatment.  Thus, neither did 
the majority of specialists comply with the diagnostic criteria of latent TB nor did 
they follow the treatment indications in the guidelines.  We have no possibility to 
conclude whether this was due to lack of interest, lack of knowledge, or for other 
reasons.  We have identified a paper on knowledge, attitudes and clinical management 
of latent tuberculosis among physicians in California.  Their replies to the various 
questions they were asked, were in 51-94% in accordance with a set of stated 
guidelines (108).  Thus, they seemed to know their guidelines reasonably well, but the 
study said nothing about how they complied with them. 
 
5.2: Study methods  
Our knowledge of the study subject was quite limited when we started.  Thus, a 
number of the challenges and limitations that we experienced, were unforeseen.  At 
the same time, these limitations were also variables that explained some of the 
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difficulties in real life when we followed the asylum seekers through our health care 
system. 
 
Systematic errors that are independent of study size include selection bias, 
information bias and confounding. 
 
Selection bias 
Selection bias occurs if the association between exposure and disease differs between 
individuals who participate in the study and those who do not.  We studied a cohort of 
asylum seekers that was registered within a defined period of time (January 2005 to 
June 2006).  We have no further information about the asylum seekers who left 
Tanum straight away and were not included in the study cohort, except that we know 
that many of them were deported or left the country.  But we found that the 
characteristics of asylum seekers where we received a response from PHC were the 
same as for those where we did not (Paper 2).  Therefore, we assume that the 
information we did receive from the municipalities was free of selection bias in the 
group. 
  
We have not analyzed any differences between the municipalities who responded and 
those who did not.  But in some cases an oral explanation was given.  The lack of 
response was explained by lack of time or vacancies among health care personnel.  In 
some cases the health personnel in question thought the study was at odds with the 
confidentiality of the clients.  We may speculate whether the municipalities who did 
respond, were more interested in TB screening and control than the ones that did not.  
We found, however, that fewer persons in the latter municipalities had started 
treatment for latent TB which may be an indication in that direction.  Still, we have no 
further information on this issue.   
 
We have limited information about the group of asylum seekers who left the country 
voluntarily or were deported during the study period.  They were characterized by the 
fact that they were not given a residence permit and hence, differed from those who 
were allowed to stay, e.g. in terms of nationality.  As they left the country they would 
not have been reported to the Norwegian National TB Register if they came down 
with active TB later.  Another group who probably also was different from the rest are 
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those who disappeared from the “official” world, went underground and took up a 
status as illegal or undocumented immigrants.  As such and since they stayed on in 
Norway, they may quite well have become the source of later TB infection.  It is 
unknown to us whether those potential cases would have been treated or notified to 
the register.  
 
Information bias 
Like selection bias, information bias is either differential or non differential.  In the 
former case misclassification for an exposure is related to the disease or 
misclassification of a disease is related to the exposure (91).  This may either result in 
an over- or underestimation of the measure of effect.  On the other hand, since non 
differential misclassification is unrelated to exposure or disease, the estimated effect 
will be closer to the null or “diluted” (91). 
 
The National TB Register was responsible for the information related to the diagnosis 
of active TB, and the initiation of treatment for latent TB.  The TB Register receives 
information from several sources.  There was uncertainty about the true identity of 
some of the participants.  For instance, asylum seekers who arrived at the National 
Reception Centre, were not given a personal identification number and some of them 
obviously had changed their names or birth dates.  Hence, it is quite likely that we 
retrieved underreported numbers from the TB Register.  This would result in a non 
differential misclassification of information.  The same reasons could have reduced 
the number of responses we received from both community and specialist health care. 
 
We have not been able to clarify with the TB Register whether the cases were 
detected by screening or not, or the duration of the symptoms of individual patients 
before diagnosis.  In paper 3 we chose to define a case as detected by screening when 
the diagnosis was made within two months after arrival.  Under- as well as over -
reporting of cases who were truly detected by screening could clearly be the result of 
our definition. 
 
Misclassification may have occurred due to lack of study information.  In some cases 
the information may have been misplaced, or lost, or was so insufficient that the data 
were of no value at all.  Consequently, some municipalities may just have classified 
 55
them as missing.  Several of the responses we did receive, had incomplete 
information, and dates were often missing.  Since we thus did not know the time 
between arrival and examination, several subjects were excluded from the analysis.  
In some cases the dates were obviously wrong (e.g. arrival after departure), but most 
often the errors only regarded a few days.  At any rate, we have no reason to believe 
that any misclassification was differential 
 
Skin tests were read by experienced nurses and recorded on the basis of induration 
and size of the infiltrate.  In case of uncertainty, the results were cross checked with 
another nurse and a consensus of results reported.  Thus, misclassification of Mantoux 
tests as either positive or negative is quite unlikely.  Even if the result of the skin test 
was not recorded, asylum seekers could be included in the follow-up study if the X-
ray or QFT was positive.  Since only 2.5% had no valid Mantoux test, a scenario like 
this would not make a substantial change of the results. 
 
Twentyseven persons were included in the follow-up study based on a positive QFT 
even if they neither had a positive X-ray nor a positive Mantoux.  However, the 
guidelines have no mention about the QFT.  Accordingly, the precise number of 
asylum seekers that should have been followed up was 2210 instead of 2237.  Our 
calculations were unaffected by their inclusion. 
 
At the time of the study the QFT kit did not include a mitogen test (positive control).  
This might have led to some false negative results.  Also, a negative QFT result per se 
could lead to under-diagnosis of active TB.  This could have reduced the number of 
cases detected with active TB in this group (Paper 4), but only to a minimal and 
negligible degree.   
 
X-rays of patients included in the QFT study that were taken in 2006 were re-read, cf 
general discussion, pp 46-47.  As a result the number of X-rays classified as positive 
increased from the original 288 to 314.  Since this was unknown at the time when the 
asylum seekers left the National Reception Centre and were relocated, some 
underreporting of positive X-rays may have occurred.  In Paper 1 and 3 these 26 
additional X-ray positive subjects were included in the analysis, but not in Paper 2 
where the focus was the follow-up of screening results.  It clearly would have been 
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inappropriate to expect that these 26 persons should have been followed up as long as 
their positive X-rays were unknown at that time.  They should probably have been 
omitted from Paper 1 too, but including them in the analysis had a minimal effect on 
the outcome.  
 
Confounding 
A confounder is a factor that is associated both with the disease and the exposure, and 
in an imbalance between the different exposure groups (91).  We restricted the 
number of explanatory variables, which on the other hand means that potential or 
unknown confounders could have been overlooked.  For instance, when we analysed 
patients with active TB and those treated for latent TB (Paper 3) the number of cases 
was quite low and did not allow us to control for instance for age in any of the 
multivariable models. 
 
Random errors 
Random errors may still remain after the systematic errors have been eliminated.  
Also, they decrease as number of participants increase (91).  The study cohort was 
selected from all asylum seekers who arrived during one and a half years.  We regard 
well over 5000 eligible persons as a reasonably large study.  However, because active 
tuberculosis is a rare disease, few cases were available for analysis.  Also, fewer 
patients than expected were treated for latent tuberculosis.  These low numbers 
naturally limited the number of variables that could be included in multivariable 
regression models.  Due to this, random errors can not be entirely ruled out. 
 
5.3: Implementation and organisational consequences 
We have conducted a study of a cohort of asylum seekers in Norway.  Since the 
numbers who arrive may vary from time to time, the follow-up rate may vary 
accordingly.  There is also a variation of the composition of asylum seekers in terms 
of country of origin.  This would in turn affect their characteristics and maybe also 
influence the follow-up and yield of the screening programme  
 
Tuberculosis screening is mandatory in Norway for immigrants from high risk 
countries.  But as we have shown in this study the follow-up of the screening results 
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in order to reach a conclusive diagnosis was fragmented and limited.  When the 
mandatory part obviously is not managed more prudently, one may question how 
health problems among asylum seekers in general are taken care of. 
 
Even if there are differences among countries regarding TB screening programmes, 
several Western countries have some kind of screening for immigrants from high 
incidence countries (24, 25, 109).  Some of the factors identified in our study might be 
helpful in planning programmes in other countries as well as our own.  For instance, it 
is well accepted that the predictive properties of QFT for tuberculosis depends on the 
population that is examined.  Nevertheless, our study has given some increased 
knowledge about the test even though few cases were available for analysis.  
 
A direct effect of this study could be a general increased awareness and knowledge 
among various categories of health personnel about tuberculosis disease.  This could 
be due to the study itself, and via information and presentation of its results to 
professionals, health and other authorities, and the public.  Health and immigrant 
authorities have already received some information about our results.  Hopefully this 
will have an impact and enhance the cooperation between the involved authorities.  
The Norwegian Institute of Public Health is revising the recommendations for follow-
up and treatment of tuberculosis in Norway, and this study may have influenced their 
contents. 
 
All asylum seekers are screened at the National Reception Centre while the 
municipalities are responsible for the primary screening of refugees and other 
immigrants, and for the follow-up of all categories including the asylum seekers.  The 
diagnostic and treatment responsibility for all with suspected, latent and overt 
tuberculosis disease on the other hand, lies with the regional health authorities.  Even 
so, the overall responsibility for public and personal health care provision to all 
immigrants lies with the national health and immigration authorities.  Since some of 
our findings most likely are as relevant for other immigrant groups in Norway as the 
one we have targeted, we find it reasonable to challenge the appropriate authorities to 
give more weight to that responsibility.  
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5.5: Future research directions 
An assessment of the cost-effectiveness of the screening programme, and how it is 
possible to implement the guidelines in a real life situation could be most useful.  
Different models of follow-up could be tested in comparative studies. 
 
Studies about treatment of latent TB where the attitudes and knowledge of specialists 
and patients are addressed are highly recommended, as are the study of factors that 
relate to – limit or enhance – treatment compliance for both active and latent TB. 
 
Studies among high risk groups in Norway that assess their knowledge and attitudes 
related to active TB and treatment of latent TB would be particularly helpful.  Also, it 
would be useful to unveil the barriers that negatively affect health seeking behaviour 
among the high risk groups.  Finally, we would encourage studies of a programme for 
active case finding and for treatment of latent tuberculosis in the same groups. 
 
Further knowledge about QFT or similar IGRAs, and their estimated predictive 
properties is needed.  This would call for a large cohort study of individuals at high 
risk for active TB. 
 
6: Conclusions 
 
The objectives of screening of immigrants are to prevent transmission of infection and 
development of disease in infected persons.  On arrival, most asylum seekers in 
Norway are screened with chest X-ray and a Mantoux test at one central unit.  As a 
result of the present study we have documented that the Mantoux testing was 
satisfactory, but we were unable to ascertain the accurate number of asylum seekers 
that had an X-ray taken.  The yield of screening was 0.7% and compares well with 
other studies.  Only one out of three persons with an elevated Mantoux test were 
followed up adequately and assessed at the local public health care level.  The clinical 
follow up by a specialist of persons with a positive X-ray or a Mantoux  15mm was 
also less than satisfactory.  Specialists were reluctant to diagnose or treat cases of 
latent tuberculosis.  The negative predictive values for a Mantoux  6mm with a 
negative QFT was equally as good as an Mantoux <15mm. 
 59
The current system for follow-up of screening results must either be reorganized, 
strengthened or abandoned.  As a minimum, a quality assurance system must be 
established and better coordination between authorities and between levels of health 
care is clearly needed.  Specialists in pulmonary medicine must be more involved in 
the revision and implementation of undisputable guidelines for treatment of latent 
tuberculosis.  A special focus on groups with particular high risk should also be 
considered. 
 60 
7: References 
1. Global Tuberculosis Control Report [database on the Internet]. WHO. 2009 
[cited April 16th, 2009]. Available from: 
http://www.who.int/tb/publications/global_report/2009/pdf/full_report.pdf. 
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. 
Global burden of tuberculosis: estimated incidence, prevalence, and mortality by 
country. WHO Global Surveillance and Monitoring Project. JAMA. 1999 Aug 
18;282(7):677-86. 
3. Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS, 
et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high 
prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J 
Infect Dis. 2001 Feb 1;183(3):469-77. 
4. Winje BA, Oftung F, Korsvold GE, Mannsaker T, Ly IN, Harstad I, et al. 
School based screening for tuberculosis infection in Norway: comparison of positive 
tuberculin skin test with interferon-gamma release assay. BMC Infect Dis. 
2008;8:140. 
5. Raviglione MC, Pio A. Evolution of WHO policies for tuberculosis control, 
1948-2001. Lancet. 2002 Mar 2;359(9308):775-80. 
6. Bjartveit K. Olaf Scheel and Johannes Heimbeck: their contribution to 
understanding the pathogenesis and prevention of tuberculosis. Int J Tuberc Lung Dis. 
2003 Apr;7(4):306-11. 
7. Statistisk årbok, 1949 ("Statistical survey 1948, report) (in Norwegian). Oslo: 
Statistics Norway1949. 
8. Heldal E. Tuberculosis in Norway and Nicaragua.  Epidemiological studies to 
strengthen prevention and control. Oslo: University of Oslo; 2004. 
9. Farah MG, Tverdal A, Selmer R, Heldal E, Bjune G. Tuberculosis in Norway 
by country of birth, 1986-1999. Int J Tuberc Lung Dis. 2003 Mar;7(3):232-5. 
10. Winje BA, Mannsåker T, Heldal E, Dahle UR. Tuberkulose i Norge i 2007. 
MSIS-rapport. 2008. 
11. Norwegian Institute of Public Health. Utredning om bruk av BCG-vaksine i 
Norge (Norwegian)(Investigation about BCG vaccination in Norway): Norwegian 
Institute of Public Health2008. 
12. Dahle UR, Eldholm V, Winje BA, Mannsaker T, Heldal E. Impact of 
immigration on the molecular epidemiology of Mycobacterium tuberculosis in a low-
incidence country. Am J Respir Crit Care Med. 2007 Nov 1;176(9):930-5. 
13. United Nations, Department of Social and Economic Affairs. International 
Migration Report 2006.  New York2006 [cited 2009 April 16.]; 74-103]. Available 
from: 
www.un.org/esa/population/publications/2006_MigrationRep/Profiles_region.pdf. 
14. Harstad I, Heldal E, Steinshamn SL, Garasen H, Jacobsen GW. Tuberculosis 
screening and follow-up of asylum seekers in Norway. A cohort study. BMC Public 
Health. 2009 May 14;9(1):141. 
15. Heldal E, Kuyvenhoven JV, Wares F, Migliori GB, Ditiu L, Fernandez de la 
Hoz K, et al. Diagnosis and treatment of tuberculosis in undocumented migrants in 
low- or intermediate-incidence countries. Int J Tuberc Lung Dis. 2008 Aug;12(8):878-
88. 
16. Historisk statistikk, immigrasjon og immigranter (Norwegian) (Historical 
statistics of immigration and immigrants).  Oslo2009 [cited 2010 April 8.]; Available 
from: http://www.ssb.no/histstat/tabeller/3-9.html. 
 61
17. Blom I. Opplysningskampanjer i kampen mot tuberkulose fram til ca 1940 
(Norwegian)[Information campaigns in the fight against tuberculosis until about 
1940]. Tidsskr Nor Laegeforen. 2002 Jan 10;122(1):73-5. 
18. Strøm A. Lærebok i sosialmedisin (Norwegian) (A textbook in social 
medicine) Oslo1968. 
19. Ongre A. [Abreugraphy and the introduction of mass X-ray screening to 
Norway]. Tidsskr Nor Laegeforen. 2008 Dec 18;128(24):2872-4. 
20. Bjartveit K. Mass miniature radiography in Norway, today and in the future. 
Scand J Respir Dis. 1972;80:31-42. 
21. Bjartveit K. Kontroll av tuberkulose : veiledning for helsepersonell. Oslo: 
Helsedirektoratet; 1977. 
22. Forskrift om tuberkulosekontroll (Norwegian)(Regulations on control of 
tuberculosis).  2002 [Dec 2th, 2009]. 
23. Nasjonalt Folkehelseinstitutt. Forebygging og kontroll av tuberkulose, en 
veileder (Norwegian)(Guidelines for prevention and control of tuberculosis). 7 ed. 
Oslo: Nasjonalt Folkehelseinstitutt; 2002. 
24. Coker R, Bell A, Pitman R, Hayward A, Watson JM. Screening programmes 
for tuberculosis in new entrants across Europe. Int J Tuberc Lung Dis. 
2004;8(8):1022-6. 
25. Coker R, Bell A, Pitman R, Zellweger J-P, Heldal E, Hayward A, et al. 
Tuberculosis screening in migrants in selected European countries shows wide 
disparities. Eur Respir J. 2006;27(4):801-7. 
26. Frothingham R, Stout JE, Hamilton CD. Current issues in global tuberculosis 
control. Int J Infect Dis. 2005 Nov;9(6):297-311. 
27. Koppak R, Bock N. How reliable is chest radiography?  Toman`s tuberculosis. 
p. 51-60. 
28. Den Boon S, Bateman ED, Enarson DA, Borgdorff MW, Verver S, Lombard 
C, J, et al. Development and evaluation of a new chest radiographic reading and 
recording system for epidemiological surveys of tuberculosis and lung disease. Int 
Journal of  tuberculosis and lung disease. 2005;9(10):1088-96. 
29. Wilcke JT, Askgaard DS, Nybo Jensen B, Døssing M. Radiographic spectrum 
of adult pumonary tuberculosis in a developed country. Respir Med. 1998;92(4):493-
7. 
30. Graham S, Das GK, Hidvegi RJ, Hanson R, Kosiuk J, Al ZK, et al. Chest 
radiograph abnormalities associated with tuberculosis: reproducibility and yield of 
active cases. Int J Tuberc Lung Dis. 2002 Feb;6(2):137-42. 
31. Zellweger JP, Heinzer R, Touray M, Vidondo B, Altpeter E. Intra-observer 
and overall agreement in the radiological assessment of tuberculosis. Int J Tuberc 
Lung Dis. 2006 Oct;10(10):1123-6. 
32. Pepper T, Joseph P, Mwenya C, McKee GS, Haushalter A, Carter A, et al. 
Normal chest radiography in pulmonary tuberculosis: implications for obtaining 
respiratory specimen cultures. Int J Tuberc Lung Dis. 2008 Apr;12(4):397-403. 
33. Marciniuk DD, McNab BD, Martin WT, Hoeppner VH. Detection of 
pulmonary tuberculosis in patients with a normal chest radiograph. Chest. 
1999;115:445-52. 
34. Perlman DC, el-Sadr WM, Nelson ET, Matts JP, Telzak EE, Salomon N, et al. 
Variation of chest radiographic patterns in pulmonary tuberculosis by degree of 
human immunodeficiency virus-related immunosuppression. The Terry Beirn 
Community Programs for Clinical Research on AIDS (CPCRA). The AIDS Clinical 
Trials Group (ACTG). Clin Infect Dis. 1997 Aug;25(2):242-6. 
 62 
35. Picon PD, Caramori ML, Bassanesi SL, Jungblut S, Folgierini M, Porto Nda 
S, et al. Differences in the clinical and radiological presentation of intrathoracic 
tuberculosis in the presence or absence of HIV infection. J Bras Pneumol. 2007 
Aug;33(4):429-36. 
36. Dasgupta K, Menzies D. Cost-effectiveness of tuberculosis control strategies 
among immigrants and refugees. Eur Respir J. 2005 Jun;25(6):1107-16. 
37. Al-Orainey IO. Diagnosis of latent tuberculosis: Can we do better? Ann 
Thorac Med. 2009 Jan;4(1):5-9. 
38. Berkel GM, Cobelens FG, de Vries G, Draayer-Jansen IW, Borgdorff MW. 
Tuberculin skin test: estimation of positive and negative predictive values from 
routine data. Int J Tuberc Lung Dis. 2005 Mar;9(3):310-6. 
39. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of 
latent tuberculosis infection: areas of uncertainty and recommendations for research. 
Ann Intern Med. 2007 Mar 6;146(5):340-54. 
40. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the 
diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177-
84. 
41. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, 
and reversion. Am J Respir Crit Care Med. 1999 Jan;159(1):15-21. 
42. Jones S, de Gijsel D, Wallach FR, Gurtman AC, Shi Q, Sacks H. Utility of 
QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected 
individuals. Int J Tuberc Lung Dis. 2007 Nov;11(11):1190-5. 
43. Winje BA, Oftung F, Korsvold GO, Mannsåker T, Jeppesen AS, Harstad I, et 
al. Screening for tuberculosis infection among newly arrived asylum seekers: 
comparison of QuantiFERON TB Gold with tuberculin skin test. BMC Infectious 
Diseases. 2008;8:65(8:65). 
44. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. 
Predictive value of a whole blood IFN-gamma assay for the development of active 
tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J 
Respir Crit Care Med. 2008 May 15;177(10):1164-70. 
45. Higuchi K, Harada N, Mori T, Sekiya Y. Use of QuantiFERON-TB Gold to 
investigate tuberculosis contacts in a high school. Respirology. 2007 Jan;12(1):88-92. 
46. Dheda K, Smit RZ, Badri M, Pai M. T-cell interferon-gamma release assays 
for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-
burden settings. Curr Opin Pulm Med. 2009 May;15(3):188-200. 
47. Higuchi K, Kondo S, Wada M, Hayashi S, Ootsuka G, Sakamoto N, et al. 
Contact investigation in a primary school using a whole blood interferon-gamma 
assay. J Infect. 2009 May;58(5):352-7. 
48. Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, 
et al. Detection and prediction of active tuberculosis disease by a whole-blood 
interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis. 2009 
Apr 1;48(7):954-62. 
49. Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, Lugos MD, et al. 
Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis 
infection. PLoS medicine. 2007 Jun;4(6):e192. 
50. Rangaka MX, Wilkinson KA, Seldon R, Van Cutsem G, Meintjes GA, 
Morroni C, et al. Effect of HIV-1 infection on T-Cell-based and skin test detection of 
tuberculosis infection. Am J Respir Crit Care Med. 2007 Mar 1;175(5):514-20. 
 63
51. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri S, et al. Serial 
testing of health care workers for tuberculosis using interferon-gamma assay. Am J 
Respir Crit Care Med. 2006 Aug 1;174(3):349-55. 
52. Leyten EM, Prins C, Bossink AW, Thijsen S, Ottenhoff TH, van Dissel JT, et 
al. Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific 
interferon-gamma assay. Eur Respir J. 2007 Jun;29(6):1212-6. 
53. Van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, et al. Within-
subject variability and boosting of T-cell interferon-gamma responses after tuberculin 
skin testing. Am J Respir Crit Care Med. 2009 Jul 1;180(1):49-58. 
54. Mori T, Harada N, Higuchi K, Sekiya Y, Uchimura K, Shimao T. Waning of 
the specific interferon-gamma response after years of tuberculosis infection. Int J 
Tuberc Lung Dis. 2007 Sep;11(9):1021-5. 
55. Richeldi L, Losi M, D'Amico R, Luppi M, Ferrari A, Mussini C, et al. 
Performance of tests for latent tuberculosis in different groups of 
immunocompromised patients. Chest. 2009 Jul;136(1):198-204. 
56. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, et al. 
Clinical evaluation of the QuantiFERON-TB Gold test in patients with non-
tuberculous mycobacterial disease. Int J Tuberc Lung Dis. 2009 Nov;13(11):1422-6. 
57. Myers WP, Westenhouse JL, Flood J, Riley LW. An ecological study of 
tuberculosis transmission in California. Am J Public Health. 2006;96(4):685-90. 
58. Buskin SE, Gale JL, Weiss NS, Nolan CM. Tuberculosis risk factors in adults 
in King County, Washington, 1988 through 1990. Am J Public Health. 
1994;84(11):1750-6. 
59. Van Burg JL, Verver S, Borgdorff MW. The epidemiology of tuberculosis 
among asylum seekers in the Netherlands: implication for screening. Int J Tuberc 
Lung Dis. 2003;7(2):139-44. 
60. Lee MS-N, Leung C-C, Kam K-M, Wong M-Y, Leung MC-M, Tam C-M, et 
al. Early and late tuberculosis risks among close contacts in Hong Kong. Int J Tuberc 
Lung Dis. 2008;12(3):281-7. 
61. Lienhardt C, Fielding K, Sillah JS, Bah B, Gustafson P, Warndorff D, et al. 
Investigation of the risk factors for tuberculosis: a case-control study in three 
countries in West Africa. Int J Epidemiol. 2005;34:914-23. 
62. Chan-Yeung M, Dai DLK, Cheung AHK, Chan FHW, Kam K-M, Tam C-M, 
et al. Tuberculin skin test reaction and body mass index in old age home residents in 
Hong Kong. J Am Geriatr Soc. 2007;55:1592-7. 
63. Chan-Yeung M, Chan FH, Cheung AH, Dai DL, Chu LW, Lam WK, et al. 
Prevalence of tuberculous infection and active tuberculosis in old age homes in Hong 
Kong. J Am Geriatr Soc. 2006 Sep;54(9):1334-40. 
64. Lonnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a 
risk factor for tuberculosis - a systematic review. BMC Public Health. 2008;8:289. 
65. Slama K, Chiang C-Y, Enarson DA, Hassmiller K, Fanning A, Gupta P, et al. 
Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. The 
International Journal of Tuberculosis and Lung Disease. 2007;11(10):1049-61. 
66. Wang JY, Lee LN, Lai HC, Hsu HL, Liaw YS, Hsueh PR, et al. Prediction of 
the tuberculosis reinfection proportion from the local incidence. J Infect Dis. 2007 Jul 
15;196(2):281-8. 
67. Moran-Mendoza O, Marion SA, Elwood K, Patrick DM, FitzGerald JM. 
Tuberculin skin test size and risk of tuberculosis development: a large population-
based study in contacts. Int J Tuberc Lung Dis. 2007 Sep;11(9):1014-20. 
 64 
68. Cook VJ, Hernandez-Garduno E, Elwood RK. Risk of tuberculosis in screened 
subjects without known risk factors for active disease. Int J Tuberc Lung Dis. 2008 
Aug;12(8):903-8. 
69. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, et al. LTBI: 
latent tuberculosis infection or lasting immune responses to M. tuberculosis? A 
TBNET consensus statement. Eur Respir J. 2009 May;33(5):956-73. 
70. Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where 
to go next? Int J Tuberc Lung Dis. 2008 Dec;12(12):1352-64. 
71. Bwire R, Nagelkerke N, Keizer ST, Annee-v. Bavel JACM, Sijbrant J, van 
Burg JL, et al. Tuberculosis screening among immigrants in the Netherlands: what is 
its contribution to public health? Neth J Med. [Review]. 2000;56:63-71. 
72. Marks GB, Bai J, Simpson SE, Sullivan EA, Stewart GJ. Incidence of 
tuberculosis among a cohort of tuberculin-positive refugees in Australia: reappraising 
the estimates of risk. Am J Respir Crit Care Med. 2000 Nov;162(5):1851-4. 
73. Hadzibegovic DS, Maloney SA, Cookson ST, Oladele A. Determining TB 
rates and TB case burden for refugees. Int J Tuberc Lung Dis. 2005 Apr;9(4):409-14. 
74. Lobato MN, Mohamed MH, Hadler JL. Tuberculosis in a low-incidence US 
area: local consequences of global disruptions. Int J Tuberc Lung Dis. 2008 
May;12(5):506-12. 
75. Ho MJ. Migratory journeys and tuberculosis risk. Med Anthropol Q. 2003 
Dec;17(4):442-58. 
76. Barr RG, Menzies R. The effect of war on tuberculosis. Results of a tuberculin 
survey among displaced persons in El Salvador and a review of the literature. Tuber 
Lung Dis. 1994 Aug;75(4):251-9. 
77. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends 
Microbiol. 2009 May;17(5):183-8. 
78. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff 
MW, et al. Rate of reinfection tuberculosis after successful treatment is higher than 
rate of new tuberculosis. Am J Respir Crit Care Med. 2005 Jun 15;171(12):1430-5. 
79. Watkins RE, Brennan R, Plant AJ. Tuberculin reactivity and the risk of 
tuberculosis: a review. Int J Tuberc Lung Dis. 2000 Oct;4(10):895-903. 
80. Prophylaxis IUATCo. Efficacy of various durations of isoniazid preventive 
therapy for tuberculosis:five years of follow-up in the IUAT trial. Bull World Health 
Organ. 1982;60(4):555-64. 
81. Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VO, Andersen AB. 
Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 
33 years of latent infection. J Infect Dis. 2002 Feb 1;185(3):401-4. 
82. Ehlers S. Lazy, dynamic or minimally recrudescent? On the elusive nature and 
location of the mycobacterium responsible for latent tuberculosis. Infection. 2009 
Apr;37(2):87-95. 
83. Bang D, Andersen AB, Thomsen VO, Lillebaek T. Recurrent tuberculosis in 
Denmark: relapse vs. re-infection. Int J Tuberc Lung Dis. 2010 Apr;14(4):447-53. 
84. Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu P, Loddenkemper R, et 
al. European framework for tuberculosis control and elimination in countries with a 
low incidence. Eur Respir J. [working group report]. 2002;19:765-75. 
85. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing 
tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 
2000(2):CD001363. 
 65
86. Rennie TW, Bothamley GH, Engova D, Bates IP. Patient choice promotes 
adherence in preventive treatment for latent tuberculosis. Eur Respir J. 2007 
Oct;30(4):728-35. 
87. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared 
with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. 
Clin Infect Dis. 2005 Mar 1;40(5):670-6. 
88. Farah MG, Meyer HE, Selmer R, Heldal E, Bjune G. Long-term risk of 
tuberculosis among immigrants in Norway. Int J Epidemiol. 2005 Oct;34(5):1005-11. 
89. Skarpaas IJK. Tuberkulosescreening av ny-ankomne innvandrere fra høy-
insidensland - fungerer det? (Tuberculosis screening of recently arrived immigrants 
from high incidence countries - is it functioning?) (in Norwegian). Tidsskr Nor 
lægefor. [comments and debate]. 2001;121(98). 
90. Johnsen NL, Steen TW, Meyer HE, Heldal E, Skarpaas IJK, Bjune G. Cohort 
analysis of asylum seekers in Oslo, Norway, 1987-1995: effectiveness of screening at 
entry and TB incidence in subsequent years. Int J Tuberc Lung Dis. 2005;9(1):37-42. 
91. Rothman K. Epidemiology.  An Introduction. New York: Oxford University 
Press; 2002. 
92. WHO Global Health Atlas.  2009 [cited 2009 Aug. 17.]; Available from: 
http://apps.who.int/globalatlas/default.asp. 
93. Harling R, Pearce M, Chandrakumar M, Mueller K, Hayward A. Tuberculosis 
screening of asylum seekers: 1 years`experience at the Dover Induction Centres. 
Public Health. 2007;121:822-7. 
94. Callister MEJ, Barringer J, Thanabalasingam ST, Gair R, Davidson RN. 
Pulmonary tuberculosis among political asylum seekers screened at Heathrow 
Airport, London, 1995-9. Thorax online. 2002;57:152-6. 
95. Holmes CB, Hausler H, Nunn P. A review of sex differences in the 
epidemiology of tuberculosis. Int J Tuberc Lung Dis. 1998;2(2):96-104. 
96. Balasubramanian R, Garg R, Santha T, Gopi PG, Subramani R, 
Chandrasekaran V, et al. Gender disparities in tuberculosis: report from a rural DOTS 
programme in south India. Int J Tuberc Lung Dis. 2004 Mar;8(3):323-32. 
97. Jimenez-Corona ME, Garcia-Garcia L, DeRiemer K, Ferreyra-Reyes L, 
Bobadilla-del-Valle M, Cano-Arellano B, et al. Gender differentials of pulmonary 
tuberculosis transmission and reactivation in an endemic area. Thorax. 2006 
Apr;61(4):348-53. 
98. Kempainen R, Nelson K, Williams DN, Hedemark L. Mycobacterium 
tuberculosis disease in Somali immigrants in Minnesota. Chest. 2001 Jan;119(1):176-
80. 
99. Wobeser WL, Yuan L, Naus M, Corey P, Edelson J, Heywood N, et al. 
Expanding the epidemiologic profile: risk factors for active tuberculosis in people 
immigrating to Ontario. CMAJ. 2000 Oct 3;163(7):823-8. 
100. Lillebaek T, Andersen ÅB, Dirksen A, Smith E, Skovgaard LT, Kok-Jensen 
A. Persistent high incidende of tuberculosis in immigrants in a low-incidence country. 
Emerg Infect Dis. 2002;8(7):679-84. 
101. Steen TW, Farah MG, Johnsen NL, Johnsen H, Johnsen UL. [Extrapulmonary 
tuberculosis among Somali immigrants in Norway](in Norwegian). Tidsskr Nor 
Laegeforen. 2003 Mar 20;123(6):818-21. 
102. Richards B, Kozak R, Brassard P, Menzies D, Schwartzman K. Tuberculosis 
surveillance among new immigrants in Montreal. Int J Tuberc Lung Dis. 
2005;9(8):858-64. 
 66 
103. Mathez C, Bangala Y, Bady P, Zellweger J-P. Active screening for pulmonary 
tuberculosis by chest x-ray among immigrants at the Swiss border. Swiss med wkly. 
2007;137:649-54. 
104. BCG Atlas [cited 2009 Nov. 27.]; Available from: http://www.bcgatlas.org/. 
105. Van den Brande P, Uydenbrouck M, Vermeire P, Demedts M. Tuberculosis in 
asylum seekers in Belgium. Eur Respir J. 1997;10:610-4. 
106. Klinkenberg E, Manissero D, Semenza JC, Verver S. Migrant tuberculosis 
screening in the EU/EEA: yield, coverage and limitations. Eur Respir J. 2009 
Nov;34(5):1180-9. 
107. Breuss E, Helbling P, Altpeter E, Zellweger J-P. Screening and treatment for 
latent tuberculosis infection among asylum seekers entering Switzerland. Swiss med 
wkly. 2002;132:197-200. 
108. LoBue PA, Moser K, Catanzaro A. Management of tuberculosis in San Diego 
County: a survey of physicians' knowledge, attitudes and practices. Int J Tuberc Lung 
Dis. 2001 Oct;5(10):933-8. 
109. Bothamley GH, Ditiu L, Migliori GB, Lange C. Active case finding of 
tuberculosis in Europe: a Tuberculosis Network European Trials Group (TBNET) 
survey. Eur Respir J. 2008 Oct;32(4):1023-30. 
 
 67
8: Appendix 
 
Appendix 8.1: Information retrieved from the computer system at the 
National Reception Centre 
 
Second name 
First name 
DUF number 
UDI number 
Country of birth 
Date of arrival at the reception centre 
Date of departure from the reception centre 
Date of tuberculin test reading  
Result of tuberculin test 
Complications of tuberculin test 
BCG scar 
Other tests (included QFT) 
Screening results sent (date) 
Asylum status (moved to new AS centre, left the country, sent out, died--) 
Results of chest X-ray 
Address when moving to private accommodation 
Reserved time at the central TB clinic and report from the central TB 
clinic 
 
General address list for asylum seeker centres, transit centres and 
municipalities in Norway. 
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Appendix 8.2: Information letter sent to primary health care about the 
study 
 
Informasjonsbrev til kommunehelsetjenesten om studien 
”Forebygging av tuberkulose blant innvandrere i Norge” 
 
Høsten 2005 fikk to innvandrerungdommer på en videregående skole i Trondheim 
smitteførende tuberkulose. Dette ble slått opp i media og utløste usikkerhet og 
spekulasjoner fra bl.a foreldre, elever, skolen og i allmennheten.  For helsevesenet 
førte det til en storstilt smitteoppsporing. En slik sak reiser spørsmålet om hvordan 
dette kan forhindres i Trondheim og landet ellers. 
 
Bakgrunn: 
Rundt 80% av pasientene med aktiv tuberkulose har innvandrerbakgrunn og de fleste 
er smittet før ankomst.  Ved ankomst skal alle innvandrere over 15 år ta lungerøntgen 
og tuberkulintest. De som er smittet og ikke har fått behandling, skal etter planen 
følges opp de nærmeste tre år. 
Forebyggende behandling antas å redusere sannsynligheten for sykdom med 60-90%. 
Veilederen ”Forebygging og kontroll av tuberkulose” (2003), anbefaler en mer aktiv 
holdning til behandling av latent tuberkulose enn tidligere.  Foreløpig er det kun en 
liten andel av alle smittede som får behandling for latent tuberkulose. 
 
Hvilke spørsmål ønsker denne studien å besvare? 
Hvordan blir asylsøkere som kommer til landet fulgt opp i kommunehelsetjenesten, 
hvem prioriteres med tanke på vurdering, og hvem blir henvist videre i tiltaks- og 
behandlingskjeden?  
Hvordan blir asylsøkerne vurdert i spesialisthelsetjenesten ?  Hvordan påvirkes 
vurderingene av den nye diagnostiske blodprøven QuantiferronTBGold? 
 
Hvem og hva skal studien undersøke?  
Studien gjelder asylsøkere som ankom Tanum asylmottak i 2005 og våren 2006 og er 
over 18 år.  Dersom de har positiv røntgen thorax, Mantoux 6mm eller positive funn 
ved QuantiferronTBGold, blir de fulgt gjennom tiltakskjeden. Det sendes først et 
registreringsskjema (som er vedlagt) til mottakskommunen, dvs dere.  Det inneholder 
spørsmål om hver enkelt asylsøker om hva som har skjedd med helseopplysningene 
fra Tanum, hvordan den enkelte ble vurdert og om han/hun ble henvist videre. Det er 
viktig med opplysninger om tidspunkt for vurdering.  Opplyser dere at asylsøkeren er 
henvist til spesialisthelsetjenesten, vil det bli sendt et annet registreringsskjema dit. 
 
Tilrådinger og tillatelser for studien:  
Studien er vurdert og tilrådd av 
• Regional komite for medisinsk forskning i Midt-Norge, 
• Sosial-og helsedirektoratet (fritak fra taushetsplikt) 
• Datatilsynet (konsesjon) 
• Arbeids- og inkluderingsdepartementet: tillatelse til å spørre mottak hvor 
personene har flyttet 
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Partnere i prosjektet er:  
• Nasjonalforeningen for Folkehelsen.  
• NTNU, Institutt for samfunnsmedisin 
• Nasjonalt folkehelseinstitutt.   
• Prosjektansvarlig: Ingunn Harstad, PhD-stipendiat og lungelege 
 
Kontakt og spørsmål: Ingunn Harstad, ingunn.harstad@ntnu.no, adresse: ISM, 
MTFS, 7489 Trondheim,   tlf 99494996 
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Appendix 8.3: Information letter sent to specialist health care about the 
study 
 
Informasjonsbrev til spesialisthelsetjenesten om studien 
”Forebygging av tuberkulose blant innvandrere i Norge” 
 
 Høsten 2005 fikk to innvandrerungdommer på en videregående skole i Trondheim 
smitteførende tuberkulose. Dette ble slått opp i media og utløste usikkerhet og 
spekulasjoner fra bl.a foreldre, elever, skolen og i allmennheten.  For helsevesenet 
førte det til en storstilt smitteoppsporing. En slik sak reiser spørsmålet om hvordan 
dette kan forhindres i Trondheim og landet ellers. 
 
Bakgrunn:  Rundt 80% av pasientene med aktiv tuberkulose har innvandrerbakgrunn, 
og de fleste er smittet før ankomst.  Ved ankomst skal alle innvandrere over 15 år ta 
lungerøntgen og tuberkulintest. De som er smittet og ikke har fått behandling, skal 
etter planen følges opp de nærmeste tre år. 
Forebyggende behandling antas å redusere sannsynligheten for sykdom med 60-90%. 
Veilederen ”Forebygging og kontroll av tuberkulose” (2003), anbefaler en mer aktiv 
holdning til behandling av latent tuberkulose enn tidligere.  Foreløpig er det kun en 
liten andel av alle smittede som får behandling for latent tuberkulose. 
 
Hvilke spørsmål ønsker denne studien å besvare? 
Hvordan blir asylsøkere som kommer til landet fulgt opp i kommunehelsetjenesten, 
hvem prioriteres med tanke på vurdering, og hvem blir henvist videre i tiltaks- og 
behandlingskjeden?  
Hvordan blir asylsøkerne vurdert i spesialisthelsetjenesten mht  forebyggende 
behandling? Hvilke behandlingsregimer brukes og hvor mange fullfører 
behandlingen?  Hvordan påvirkes vurderingene av den nye diagnostiske blodprøven 
QuantiferronTBGold? 
 
Hvem og hva skal studien undersøke? Studien gjelder asylsøkere som ankom 
Tanum asylmottak i 2005 og våren 2006 og er over 18 år.  Dersom de har positiv 
røntgen thorax, Mantoux 6mm eller positive funn ved QuantiferonTBGold, blir de 
fulgt gjennom tiltakskjeden. Det sendes først et registreringsskjema til 
mottakskommunen med spørsmål om hver enkelt asylsøker, hvordan den enkelte ble 
vurdert og om han/hun ble henvist videre. Dersom det ble opplyst at asylsøkeren er 
henvist til spesialisthelsetjenesten, vil det bli sendt et annet registreringsskjema til 
dere. Det inneholder spørsmål om hvordan den enkelte er vurdert, undersøkt og om 
det er funnet indikasjon for forebyggende behandling. 
 
Tilrådinger og tillatelser for studien: Studien er vurdert og tilrådd av: 
• Regional komite for medisinsk forskning i Midt-Norge, 
• Sosial-og helsedirektoratet (fritak fra taushetsplikt) 
• Datatilsynet (konsesjon) 
• Arbeids- og inkluderingsdepartementet: tillatelse til å spørre mottak hvor 
personene har flyttet 
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Appendix 8.4: Primary health care study form 
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Abstract
Background: About 80% of new tuberculosis cases in Norway occur among immigrants from high incidence
countries. On arrival to the country all asylum seekers are screened with Mantoux test and chest x-ray aimed to
identify cases of active tuberculosis and, in the case of latent tuberculosis, to offer follow-up or prophylactic
treatment.
We assessed a national programme for screening, treatment and follow-up of tuberculosis infection and disease
in a cohort of asylum seekers.
Methods: Asylum seekers  18 years who arrived at the National Reception Centre from January 2005 to June
2006, were included as the total cohort. Those with a Mantoux test  6 mm or positive x-ray findings were
included in a study group for follow-up.
Data were collected from public health authorities in the municipality to where the asylum seekers had moved,
and from hospital based internists in case they had been referred to specialist care.
Individual subjects included in the study group were matched with the Norwegian National Tuberculosis Register
which receive reports of everybody diagnosed with active tuberculosis, or who had started treatment for latent
tuberculosis.
Results: The total cohort included 4643 adult asylum seekers and 97.5% had a valid Mantoux test. At least one
inclusion criterion was fulfilled by 2237 persons. By end 2007 municipal public health authorities had assessed 758
(34%) of them. Altogether 328 persons had been seen by an internist. Of 314 individuals with positive x-rays, 194
(62%) had seen an internist, while 86 of 568 with Mantoux  15, but negative x-rays (16%) were also seen by an
internist. By December 31st 2006, 23 patients were diagnosed with tuberculosis (prevalence 1028/100 000) and
another 11 were treated for latent infection.
Conclusion: The coverage of screening was satisfactory, but fewer subjects than could have been expected from
the national guidelines were followed up in the community and referred to an internist. To improve follow-up of
screening results, a simplification of organisation and guidelines, introduction of quality assurance systems, and
better coordination between authorities and between different levels of health care are all required.
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Background
As tuberculosis (TB) in native populations in Western
countries decreases, the relative importance of cases
among immigrants increases. Latent tuberculosis is preva-
lent in immigrants, and may result in an increased inci-
dence for many years after immigration [1,2].
Many Western countries carry out screening immediately
after arrival, but programmes for immigrants from high
incidence countries vary widely between them, and their
documented impact is sparse. While some countries focus
mainly on diagnosing active pulmonary tuberculosis, oth-
ers follow up high risk individuals, or aim at preventing
new cases through BCG immunisation or treatment of
latent tuberculosis [3,4].
For public health it is most important to identify cases of
pulmonary tuberculosis and the majority of them can be
detected by chest x-ray [1,5]. Still many cases of extra-pul-
monary tuberculosis and latent tuberculosis may thus be
overlooked. A tuberculin skin test is often used in addi-
tion to x-ray, but has several limitations [6]. Recently, new
interferon gamma release assays have been introduced,
with promising results for diagnosing latent tuberculosis
and may become a useful addition to the screening pro-
gramme [7].
In Norway, the incidence of tuberculosis in the general
population gradually decreased until the late 1980's.
Thereafter the number of new cases has remained low and
was 6.3/100 000 population in 2006 [8]. During the last
25 years the characteristics of incident cases have changed,
and the active disease now stem from imported strains
rather than person to person transmission within the
country [9]. Somalia is the country of origin for most new
cases.
Previously, the main focus of the Norwegian tuberculosis
control programme was on early case detection of active
disease and follow-up without treatment of the latent
form. In 2002 the European working group on tuberculo-
sis control and elimination in low incidence countries
(WHO, International Union Against Tuberculosis and
Lung Disease, Royal Netherlands Tuberculosis Associa-
tion) recommended a new strategy. It aimed to reduce the
prevalence of tuberculosis infection and also included
prophylactic therapy [10].
The same year new regulations for tuberculosis control
were introduced in Norway. These emphasised a contin-
ued need to screen immigrants from high incidence coun-
tries after arrival, as well as others with high risk, and to
follow up those with abnormal findings [11]. The corre-
sponding national guidelines, that were issued by the
national health authorities to all health personnel
engaged in TB management and care, promoted more vig-
orous treatment of latent tuberculosis [12].
Public health care in Norway is organised in two levels
where the municipal authorities are responsible for pri-
mary health care. This includes infectious disease control
within the community. Patients in whom screening out-
come implies a more detailed and targeted follow-up, are
referred to specialist care in state-owned hospitals.
Recommended screening and management of tuberculosis
Asylum seekers and refugees (table 1) are subgroups of
immigrants with particularly high risk for tuberculosis
[13,14]. Hence, on arrival in Norway, all asylum seekers
are referred to the National Reception Centre outside Oslo
for registration, management of immediate medical
needs, and compulsory tuberculosis screening (figure 1
and table 2). Screening includes a Mantoux test and chest
x-ray for everyone over 15 years of age.
According to the guidelines, asylum seekers with a chest x-
ray suggestive of tuberculosis disease, as well as everyone
who reports symptoms of tuberculosis, should be referred
directly to the Central TB Clinic at Ullevaal University
Hospital, Oslo, for further examination. It is clearly stated
that in addition to a positive x-ray, a Mantoux test  15
mm should lead to a direct referral to an internist [12].
When leaving the National Reception Centre, asylum
seekers are directed to one of several local asylum seeker
centres or transit centres in communities throughout the
country. If an individual has to await the outcome of
examination, or if treatment is started, the whole family
will stay at one specially designated Transit Centre for TB
Treatment until the treatment is completed (figure 1).
Those who initially stay in a transit centre later move on
to an asylum seeker centre. On the other hand, they may
also leave the country on their own or be sent out at any
time. Sometimes, asylum seekers find private accommo-
dation on their own with help from family or others.
Screening results are mailed to the respective municipal
health authorities, and everyone with a Mantoux test of 6–
14 mm should be clinically examined in primary health
care and interviewed about other TB risk factors [12]. An
HIV test is not compulsory, but is taken if deemed clini-
cally relevant. Whenever definite risk factors are identi-
fied, all patients should be referred to an internist who is
responsible for ensuring timely clinical examination and
a sputum test, and any other relevant diagnostic work-up.
If tuberculosis disease is diagnosed or treatment for latent
tuberculosis is started, a nominal notification is sent to
the National Tuberculosis Register.
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Flow of asylum seekersigure 1
Flow of asylum seekers. Primary Health Care (PHC) form sent to first municipality (transit centres, asylum seeker centres, 
or private accommodation) 2: PHC form sent to second municipality (asylum seeker centres or private accommodation) 3: 
Specialist form sent to the Central TB Clinic and to other hospital based specialists (internists).
National Reception Centre
Screening with chest x-ray and Mantoux
Central TB Clinic3:
examination
Municipality 1
Transit Centre for TB 
Treatment1
Municipality 1
Private accomodation or
asylum seeker centre1
Specialist consultation3
Treatment
TB disease/
latent TB
National TB Register TB coordinator
Municipality 2/ private accommodation
or asylum seeker centre2
Suspected
TB disease
Disproved 
TB disease
Completed 
treatment
for TB disease
Moving to new municipality
TB 
disease
No treatment.
Follow up if latent TB
/ no follow up if no latent TB
Municipality 1
transit centre1
Moving to first municipality
from National Reception Centre
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Information about asylum seekers is readily available
since they are all received through a single National
Reception Centre.
We aimed to assess to what extent the national recom-
mendations for screening, treatment and follow-up of
tuberculosis disease and infection among asylum seekers
had been implemented at the primary and specialist
health care levels in Norway [11,12].
Methods
Study population
All asylum seekers  18 years who arrived at the National
Reception Centre from January 2005 to June 2006, were
eligible for study inclusion except those that had left the
centre without a forwarding address, had left the country,
had been deported, or had died before leaving the centre.
Inclusion into the study group for follow-up was ascer-
tained from information held in the data base at the
National Reception Centre. The criteria for inclusion were
either a positive Mantoux test or a positive chest x-ray. The
former was defined as Mantoux  6 mm, (PPD: RT 23, 2
TU from SSI, Copenhagen, Denmark).
X-ray films were taken at the National Reception Centre
and interpreted by two independent readers, a pulmonol-
ogist and a radiologist. The results were later recoded for
this study. A positive x-ray included pleural pathology,
Table 1: Definitions of "asylum seeker" and "refugee"
Asylum seeker1 A person who on his or her own initiative, and without prior notification, asks the authorities in Norway for protection and 
recognition as a refugee. The person is called an asylum seeker until a decision has been made on the application.
Refugee A person who either has been granted residence permit before arrival, through the UN system, or arrived as an asylum 
seeker and has been granted protection as refugee after application.
1http://www.udi.no/upload/English/FactSheet/FaktaarkAsylEngelsk.pdf
Table 2: Kind and characteristics of institutions attending asylum seekers
Institutions 
(total number)
Functions Health care level Staff Source of information 
for the study
National Reception 
Centre (1)1
Short term.
All asylum seekers (AS) on 
arrival to Norway. 
Screening by chest x-ray 
and Mantoux.
Primary health care (PHC) 
paid for by national
government.
PHC officer or nurse Information from the 
computer system of the 
National Reception 
Centre.
TB Treatment Transit 
Centre (1)1
Short or long term. 
Treatment of patients with 
active TB, or potential 
patients waiting for 
consultation or 
examination results. Family 
members are included.
PHC paid for by national
government
PHC officer or nurse Filled in PHC registration 
forms2
Central TB Clinic (1)1 Out patient.
AS referred directly from 
the National Reception 
Centre or from other 
levels. Focus is active TB.
Hospital based specialist 
health care.
Specialists in pulmonary 
medicine
Filled in specialist 
registration form3
Transit centre (4)1 Short term stay. AS who 
wait for an interview by 
police or for being 
deported.
PHC paid for by national
government
PHC officer or nurse Filled in PHC registration 
forms2
Asylum seeker centre 
(ca 100, January 2005)
Longer stay. Staying there 
till they get a permanent 
residency or are deported.
Municipal authorities 
directly responsible for 
health care.
PHC officer or nurse Filled in PHC
registration forms2 or 4
Specialist health care Out patient.
Examine and treat AS after 
referral from primary 
health care
Hospital based specialist 
care.
Hospital specialists, 
pulmonary or internal 
medicine
Filled in specialist
registration form3
1: Number of centres, 2: PHC forms sent to the first municipality after the National Reception Centre, 3: Specialist forms, 4: PHC forms sent to the 
second municipality after the National Reception Centre
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pulmonary, hilar or mediastinal calcifications, or paren-
chymal pathology.
An interferon gamma release assay test (QuantiFERON®
TB Gold in-tube test, Cellestis Ltd, Carnegie, Victoria, Aus-
tralia, QFT) had been performed in a previous study of a
subset of 912 eligible persons [15].
Data collection
Information on demographics and initial screening
results was collected from the data base at the National
Reception Centre. Follow-up information was obtained
by using two different study forms. First, a local primary
health care (PHC) form was sent to the public health phy-
sician in the municipality where the asylum seekers had
moved to. If the person in question had moved to a sec-
ond municipality, the same form was sent there (figure 1).
Second, a specialist form was sent to the Central TB Clinic
whenever findings at the National Reception Centre had
indicated that a referral was indicated. It was sent to other
hospital internists throughout the country when the PHC
form positively confirmed that an individual had been
referred to specialist care (figure 1).
Both forms collected information about demographics,
registration and flow of information, previous history and
other diseases, TB risk factors, symptoms, clinical exami-
nation and findings, plans for follow-up or referrals, and
relocations of study participants. The municipalities were
asked whether the asylum seeker had been examined or
interviewed, and if so, by whom: physician, community
health nurse, or regular nurse. Any referrals were recorded:
x-rays, specialist health care, or others. In case of no refer-
ral, the reason why was recorded: not indicated, the
patient did not want a referral, or other reasons. Relevant
dates and numbers were also recorded.
Name and birth date on everyone included in the study
group were checked against the National Tuberculosis
Register. The latest update of the register took place on
December 31st 2006.
Data handling and analysis
Study forms were scanned and entered into SPSS for Win-
dows, version 14 (Chicago, IL, USA). Comments and
administrative information were coded manually and
entered to the same data file.
Frequencies were analyzed with proportions and 95%
confidence intervals (CI). Groups were compared on
demographics, and positive x-rays were also compared on
x-ray codes. Prevalence < 0.05 were considered statistically
significant.
Study ethics
The Regional Committee for Medical Research Ethics
approved the study. The Norwegian Data Inspectorate, the
Directorate for Health and Social Affairs, the Ministry of
Labour and Social Inclusion, and the Research Committee
at Ullevaal University Hospital all gave their permission.
Results
Among the 5112 asylum seekers  18 years who arrived at
the National Reception Centre from January 2005 to June
2006, 4643 (91%) were eligible for study inclusion and
are hereafter referred to as the total cohort. Among this
cohort, there were 3222 (69%) males and 3333 (72%)
were in the 18–34 year old age group. They came from 90
different countries, and Iraq, Somalia, Russia, Afghani-
stan, and Serbia and Montenegro contributed most, i.e.
2434 persons (52%). Coverage of a valid Mantoux test
was 4526 (97.5%), the yield of a Mantoux  6 mm was
2127 (46%) and a positive chest x-ray 323 (7%) individ-
uals, respectively. A positive QFT test was used as the only
inclusion criterion for 28 participants.
The follow-up study group
Of the 2293 asylum seekers with at least one positive
inclusion criterion, 2237 were included in the follow-up
study because 56 individuals who were eligible for inclu-
sion had left the National Reception Centre with no for-
warding address, left the country, been deported, or died
before leaving the centre.
The proportion of males was higher in the youngest age
group. More participants came from Europe and Asia in
the older age group while there were more Africans in the
youngest one. The five most frequent countries of origin
were the same as in the total cohort.
Registration forms to local municipalities were sent to 81
different asylum seekers centres. From January 2005 to
January 2007 there was a reduction in the number of asy-
lum centres from 100 to 65, i.e. many centres that were
contacted initially, closed down during the study period.
We received information about 1625 (73%) of those asy-
lum seekers who had moved out into the municipalities,
and 220 (93%) of those who had been referred to special-
ists (figure 1).
Study end points
Among 1326 persons with negative x-rays and a Mantoux
test result between 6 and 14 mm, 372 (28%) were seen in
PHC, of whom 188 of 572 (33%) Africans were seen,
compared to 45 of 221 (20%) Europeans and 129 of 494
(26%) Asians. Of the 568 persons with negative x-ray and
Mantoux  15 mm, 86 (16%) were seen by an internist. Of
all the observed proportions, the differences between Afri-
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cans and Europeans seen in PHC with Mantoux 6–14 mm
was the only one that was statistically significant (p <
0.05).
Further, of the 314 persons with abnormal x-ray findings,
194 ones (62%) were seen by an internist. While 165 of
235 (70%) with parenchymal findings were seen, 20 of 61
(33%) of those with other x-ray findings were seen and
the differences were statistically significant (p < 0.05).
Among subjects with positive x-rays, 76 of 115 (66%)
Africans, 73 of 128 (57%) Asians and 38 of 55 (69%)
Europeans were seen and the proportions were not signif-
icantly different.
Altogether 758 were assessed in one way or another in
PHC (figure 2). Of these, 673/2237 (30%) persons had
actually been seen by a physician (n = 380) or nurse (n =
293) at this care level. Another 85 persons were referred
directly from PHC either for chest x-ray or to a specialist
without being seen personally.
Personal encounters took place a median of 9 weeks after
arrival (range 0–124). Thus, 302 of 439 (69%) persons
with valid dates were seen within 13 weeks of arrival and
376/439 (86%) within 26 weeks.
Three hundred and twenty-eight persons, i.e. 15% of the
study group, were seen by an internist. They included 185
persons who were either examined at the Central TB
Clinic and/or 169 who were examined by other hospital
internists (figure 2). In all 236 persons were referred from
PHC to an internist. Median time from arrival in the coun-
try to the internist visit was 25 weeks (range 0–114). The
median time from the referral letter was received till the
internist consultation took place was 10 weeks.
A total of 794 patients (35% of the study group) were seen
either by primary and/or secondary health care providers.
When the cohort of 2237 asylum seekers were matched
with the National Tuberculosis Register (31st December
2006), 23 (1028/100 000) cases of active tuberculosis
were identified. Thirteen were diagnosed within 3 months
of arrival, 14 within 6 months, and 19 within 12 months.
Of those cases, 11 were from Somalia, three from Russia
and two from Serbia and Montenegro. Four cases were
reported among the 27% of asylum seekers with no reply
from PHC, one was seen at the Central TB Clinic, while
the other three were diagnosed five, 17 and 33 weeks after
arrival. We further identified 11 cases who had started
treatment for latent tuberculosis, all had a Mantoux test 
10 mm, and seven came from Africa.
Discussion
Of 4643 asylum seekers, tuberculosis screening identified
2237 persons (48%) who should have been assessed and
followed up by primary or specialist health care. Between
6–24 months after arrival, only one third of those at high
risk had been assessed by community health care, while
15% had seen an internist. Twenty-three persons were
diagnosed with tuberculosis disease and 11 had started
treatment for latent tuberculosis.
Limitations of the study
The study design implied that information about assess-
ment and referrals depended on an initial response from
PHC. The lack of response clearly reduced the number
brought to our attention about asylum seekers who were
referred to and seen by a specialist. Information collected
through the study forms was limited to what we could
retrieve from patient records. Thus, if records were not
found or were incomplete, the numbers assessed and/or
referred could be too low.
We do not know if the 27% with no response from PHC
were assessed and followed-up to the same degree as those
with a response. One possibility is, on the whole, that
municipalities that did not respond were less interested in
TB than those that did.
Total numbers of asylum seekers with an indication for fol-low-up of TB creening se n or assessed i  Norwegian primary and/or speci list health ca e cf. t xtFigure 2
Total numbers of asylum seekers with an indication 
for follow-up of TB screening seen or assessed in 
Norwegian primary and/or specialist health care cf. 
text.
Study population
at the National Reception 
Centre
N=2237
Asessed in primary
health care
N=758 (673 seen and
85 referred directly)
Seen by 
specialist 
after referral
N=169
Seen by specialist
at the Central TB
Clinic
N=185
Totally seen
by specialist
N=328
Totally seen 
by primary and/or 
specialist health
care N=794
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We had no access to information about asylum seekers
leaving the country, and if the interval before they did so
made any difference to our results. This limits our poten-
tial to give exact rates for those that should have been seen
in PHC or by a specialist. Because of insufficient registra-
tion, and since the systems for handling follow-up of
screening results and referrals due to symptoms are mixed
together, we cannot say exactly how many of the TB cases
were found through the screening system or through refer-
rals because of symptoms. We are also unable to assess the
incidence of TB at certain times after arrival. If many had
left at an early stage, the denominators would decrease,
with a consequent increase in rates. Dates for assessment
or referral were often left open on the forms or were obvi-
ously incorrect.
Because asylum seekers do not have a personal identifier,
the cases found through the match with the TB Register
could have been reduced, and this may also have reduced
the numbers of study individuals recorded in the munici-
palities and hospitals to where the study forms were sent.
Apparently, this would limit both their compliance to
national guidelines and the numbers found through the
TB Register.
Several local authorities could not provide health records
for asylum seekers who had moved on, or where asylum
seeker centres had been abandoned during the study
period. This also limited the quality of our study.
Study endpoints
The entry screening was satisfactory and only 2.5% of asy-
lum seekers had no registered Mantoux result. Voluntary
screening at a similar centre in the UK reported that 94%
were screened [16]. Most of the 469 asylum seekers who
were not included in the total cohort left the country or
were deported straight away and were of limited interest
from a screening point of view. The number of the total
cohort who actually got an x-ray taken, was impossible to
retrieve from the data recording system at the National
Reception Centre.
Everybody with a Mantoux 6–14 should have been seen in
PHC, but only 28% of them were. Informal information
given as reasons for this insufficient follow-up, were an
absence of personal information (wrong address, name or
date of birth), lack of resources, low priority, and insuffi-
cient knowledge of the guidelines or how they should be
interpreted. Sometimes, patients were referred separately
to x-ray, but not to a specialist. That procedure was appro-
priate given the previous guidelines, but not the current
ones [11]. It took a median time of 9 weeks from arrival
in Norway until assessment took place, but the range was
0–124 weeks. Thus, we speculate that several asylum seek-
ers were not assessed unless they developed symptoms
which brought them to the attention of the health author-
ities.
Follow-up of x-ray findings is the most important part of
the screening, and we found that only 62% of those with
initial positive findings were seen by an internist. This was
most likely an organisational problem between the
National Reception Centre and the Central TB Clinic.
There was most probably some selection of follow up at
the Central TB Clinic since relatively more cases with
parenchymal findings were seen by an internist.
The guidelines recommend that all cases with Mantoux 
15 mm should be referred directly to an internist, but they
do not specify if the individual should be seen at the Cen-
tral TB Clinic or at the nearest institution after they have
moved to their new home municipality. Only 16% of
those with Mantoux  15 mm were finally seen by an
internist. Generally, they were not referred to the Central
TB Clinic, and arguments such as an expected short stay at
the National Reception Centre, the general high workload
at the Central TB Clinic, and uncertainty about how long
the asylum seekers would stay in the country were used to
explain this. However, these subjects were not referred to
a specialist after they had arrived in their new municipal-
ity, either.
The median time from the referral letter was received until
the specialist consultation took place was 10 weeks. This
seems appropriate if the question was an assessment for
latent TB, but not if the question was to rule out active dis-
ease.
We matched study group individuals with the National
Tuberculosis Register which allowed us to estimate point
prevalence and an incidence rate. However, since many
asylum seekers could have left the country without notifi-
cation, this limited the exact population at risk. It also
made it difficult for both health care levels to follow up
the initial cohort. Conversely, these limitations realisti-
cally mimic the complexity of information flow and refer-
ral data for this group of individuals.
We identified 23 cases (1%) of the study group with tuber-
culosis disease between 6 to 24 months after arrival. Some
incident cases that occurred after screening may have been
mixed up with the prevalent ones, and we are unable to
estimate how many cases of active TB we missed through
lack of adherence to the guidelines. Studies from other
countries have reported prevalences of between 0.1–1.2%
[13,16-18], but valid comparisons between our and other
studies require more information about the different
study populations.
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The number of asylum seekers who were treated for latent
TB was lower than expected and potential reasons for this
will be discussed in a forthcoming paper. National guide-
lines vary between countries, yet other studies show a lack
of adherence to guidelines similar to ours [19,20]. Com-
parisons between studies are made even more difficult
because treatment indications for latent TB vary consider-
ably.
Information flow and data ascertainment
An overall problem was that the flow of health informa-
tion between administrative levels did not keep up with
the movements of individual asylum seekers. Similar dif-
ficulties have been reported by others and compare well
with our results [19-21].
Lack of adequate information between asylum seeker cen-
tres and primary or specialist health care was another
problem we identified.
Personal characteristics
Asylum seekers are registered with their name and date of
birth on arrival, but do not get the personal identifier all
Norwegian residents have until they have stayed in the
country for several months. As a result of registration
errors or because their name or date of birth are misstated,
an asylum seeker may have several different identities and
is not recognised in many public registers. Also, some may
have entered Norway several times during the study
period, resulting in a further negative influence on assess-
ment or treatment. All these factors made follow-up quite
difficult.
Asylum seekers move several times and frequently with-
out reporting or informing authorities about their new
address. They usually have little knowledge of the Norwe-
gian language, their access to an interpreter is limited, and
they may have a different conception of health issues. All
are reasons why appointments were not kept.
Consequences for policy
Despite our current and detailed guidelines, we may spec-
ulate that the inadequate follow-up was due to a complex
organisation, insufficient or inappropriate information
handling procedures, insufficient awareness and adher-
ence to the guidelines, and limited focus on the TB issue
by the involved health care providers and society at large.
Further data analyses may cast light on some of these
assumptions.
We believe that both the organisation and the guidelines
should be simplified. Furthermore, a quality assurance
and a report system for information flow and personal fol-
low-up are needed. Cooperation between immigration
and health authorities should make sure that municipali-
ties with asylum seekers centres have a more streamlined
and efficient system for follow-up of tuberculosis screen-
ing with special staff dedicated to implementing it.
Conclusion
TB screening of asylum seekers identified a prevalence of
1% of active tuberculosis in the study group included for
follow-up. In addition we found a considerable propor-
tion of subjects at increased risk. We identified inadequate
handling of screening results at all levels of care, with too
few patients treated for latent tuberculosis.
To improve follow-up of screening results, a simplifica-
tion of organisation and guidelines, introduction of qual-
ity assurance systems, and better coordination between
authorities and between different levels of health care are
all required.
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Abstract 
Background 
Most new cases of active tuberculosis in Norway are presently caused by imported 
strains and not transmission within the country.  On arrival screening for tuberculosis 
with a Mantoux test of everybody and a chest X-ray of those above 15 years of age is 
compulsory for asylum seekers.   
We aimed to assess the effectiveness of the tuberculosis entry screening of a cohort of 
asylum seekers.  Cases detected by screening were compared with cases detected 
later.  Further we have characterized cases with active tuberculosis.  
Methods 
All asylum seekers arriving at the National Reception Centre from January 2005 till 
June 2006 with an abnormal chest X-ray or a Mantoux test  6 mm were included in 
the study and followed through the health care system.  Those included were matched 
with the National Tuberculosis Register by the end of May 2008. 
Cases reported within two months after arrival were defined as being detected by 
screening. 
Results 
Of 4643 eligible asylum seekers, 2237 were included in the study.  Altogether 2077 
persons had a Mantoux  6 mm and 314 a positive X-ray.  Among them, 28 cases of 
tuberculosis were detected, fifteen by screening, and thirteen 4-27 months after 
arrival.  Positive X-rays on arrival were more prevalent among those detected by 
screening.  Female gender and Somalian origin increased the risk for active TB.   
Conclusion 
In spite of an imperfect follow-up of screening results a reasonable number of TB 
cases were identified by the programme.  Most of them having pulmonary TB.   
 4 
Background 
 
In recent years most new tuberculosis (TB) cases in Norway have occurred among 
immigrants from high incidence countries.  Rarely, new cases are due to transmission 
within the country [1]. 
 Low incidence countries have diverse policies on entry screening of 
immigrants from high incidence countries.  They range from no screening at all, to 
pre-immigration screening or screening after arrival [2-4].  There is an ongoing 
discussion about the content and effect of screening programmes to control 
tuberculosis [5, 6].  Different studies of screening of tuberculosis among immigrants 
have given TB prevalences that vary from 0.1-1.2% [7-10].  Differences in the 
characteristics of the populations that were screened and the programmes themselves 
naturally will affect the yield.  
 Previous studies have shown differences between cases detected by or outside 
the screening programme.  Cases found by screening have fewer symptoms and fewer 
positive cultures [11, 12].  Previous studies have shown that a quite high number of 
TB cases in immigrant populations were found several years after immigration [5, 6, 
13]. 
Risk factors for tuberculosis can be divided into the risk for being infected and 
the risk for developing disease.  Typical risk factors for being infected are for instance 
poverty and a history of being incarcerated.  On the other hand, the risk for 
developing disease is related to recent infection, reduced immunity from other 
diseases like HIV or medical treatment, intake of alcohol, smoking, body weight loss 
and country of origin [14-19].  
 
 5
The tuberculosis screening programme in Norway 
It is mandatory to screen all asylum seekers for tuberculosis when they arrive to 
Norway.  The aim of the screening is to diagnose and treat active TB, and diagnose 
cases with latent TB either for treatment or a three year follow-up programme [20].  
However, the programme does not clearly differentiate between screening for active 
and latent disease.  
The National Reception Centre outside Oslo performs a Mantoux test of everybody 
and a chest X-ray of persons above the age of 15.  Persons who report clinical 
symptoms of TB, or have a positive X-ray, has to be referred to the Central TB Clinic 
in Oslo for assessment of TB disease.  Persons with a Mantoux test  15 mm shall be 
referred to the specialist health care, where a chest physician or an internist normally 
will see the patient for evaluation of TB disease or infection.  Those with a Mantoux 
test 6-14 mm shall be followed up by primary health care (PHC).  Whenever definite 
risk factors are found, the patient shall be referred to a specialist [21].  However, 
diagnosis of latent TB remains a challenge and recommendations for diagnosis and 
follow-up are ambiguous.  TB disease is diagnosed on the basis of symptoms, clinical 
examinations, chest X-rays and the test of a bacteriological sample.  In Norway, only 
specialists are allowed to start TB treatment.  Whenever a TB diagnosis is confirmed 
and/or treatment for TB is started, a nominal notification is sent to the National 
Tuberculosis Register.  When asylum seekers leave the Reception Centre they move 
to other asylum seekers centres throughout the country or to private accommodations.  
  Surveillance data for TB are available in Norway, but not for asylum seekers 
specifically.  An earlier Norwegian study on chest X-ray results from entry screening 
of asylum seekers, concluded that an improved follow-up of persons with an 
abnormal X-ray was necessary [22].  Among cases not diagnosed by arrival screening 
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they found that 11(14%) had been inadequately followed up.  A previously published 
paper of the present cohort showed that 194/314 (62%) with an abnormal X-ray had 
been seen by an internist, and altogether 758/2237 (34%) with a positive Mantoux test 
and/or an abnormal X-ray had been followed up at the primary health care level.  
Inadequate handling of screening results was found at all levels of care [23].   
The aim of the present study is to assess the effectiveness of diagnosing active 
TB by the tuberculosis entry screening programme, in a cohort of asylum seekers.  
We are comparing patients who were diagnosed by the screening programme with 
those who were detected later.  Further we aim to characterize all cases of active 
tuberculosis.  
 
Materials and methods 
Study population  
All asylum seekers above the age of 18, that arrived at the National Reception Centre 
from January 2005 till June 2006 were screened with a chest X-ray and a Mantoux 
test.  They were included in the study if they were available for follow-up and had an 
abnormal chest X-ray, a Mantoux test  6 mm and/or a positive QuantiFERON® TB 
Gold (QFT) test.  During the study period 5112 asylum seekers were screened.  Four 
hundred and sixty nine of them could not be followed up because they were either 
deported, dead or had no registered address.  Of 4643 (called the total cohort) 2293 
had positive study inclusion criteria.  However, 56 were lost from the National 
Reception Centre and hence, 2237 study participants were included [23]. 
An abnormal chest X-ray was defined as parenchymal or pleural pathology, or 
calcifications.  The X-rays were taken at the National Reception Centre, interpreted 
by two independent readers and later recoded for this study.  A positive Mantoux test 
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was defined as  6 mm (PPD: RT 23, 2TU from SSI, Copenhagen, Denmark).  An 
interferon- release assay test: (QuantiFERON® TB Gold in-tube test, Cellestis Ltd, 
Carnegie, Victoria, Australia, QFT) was done as a separate study on a subgroup of 
912 participants [24].   
 
Collection of study information 
Information about demographics and screening results were collected from the data 
files at the National Reception Centre.  Further information was collected by one 
registration form that was sent to the public health care official in the municipality to 
where the asylum seeker had moved, and if they reported that any person in question 
had moved on, the same form was sent to the appropriate municipality.  If the PHC 
form indicated that a referral had taken place, a specialist form was sent to the 
appropriate internists.  A specialist form was also sent to the Central TB Clinic when 
we received information from the National Reception Centre that an asylum seeker 
had either been referred there or had an abnormal X-ray.  Both forms collected 
recorded information about assessment by health care personnel, plans for follow-up 
and why the patient had been referred.  In addition we collected information about 
current addresses or relocations of study participants.   
A match by name and date of birth between everyone who were included in 
the study group and the National Tuberculosis Register was done in May 2008.  The 
register holds information about localisation of disease, culture results, the individual 
physician who had reported the case, and some background information about the 
specialist referral.   
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Cases reported to the National Tuberculosis Register within two months after 
arrival were categorized as detected by screening in contrast to those who were 
detected later.   
Data registration and analyses 
Study forms were scanned and entered into the SPSS program (SPSS for Windows, 
version 16, Chicago, Ill, USA).  Comments and administrative information were 
coded manually and entered to the same data file. 
The study group and the TB cases were described by proportions and 95% 
confidence intervals (CI).  Time from arrival till notification to the Tuberculosis 
Register was approximated to closest number of total months. 
The primary outcome diagnosed as active tuberculosis or not, were analysed 
with logistic regression.  The assessed regressors were stratified age, gender, country 
of origin (Somalian or not), marital status (married or not), Mantoux ( 10 or not, and 
 15 or not) and X-ray (abnormal or not).  Variables in the univariate analysis that 
changed the odds ratio (OR) of the other variables with 0.2 or more were entered into 
the multivariable analysis.  The model was checked for correlations and interactions.   
Due to low number of cases, the secondary outcome; i.e cases that were 
detected by screening or not, was studied only by univariate logistic regression.  
Additional regressors for the secondary outcome were a diagnosis of pulmonary TB 
(as opposed to extra-pulmonary TB) (yes/no) and a positive culture (yes/no).  
 
Ethics 
The Regional Committee for Medical Research Ethics approved the study.  The 
Norwegian Data Inspectorate, Directorate for Health and Social Affairs, Ministry of 
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Labour and Social Inclusion, and the Research Committee at Ullevaal University 
Hospital all gave their permission.  
 
Results 
There were 3222 (69%) males and 3333 (72%) were between 18 to 34 years in the 
total cohort.  Iraq, Somalia, Russia, Afghanistan and Serbia and Montenegro were the 
five countries of origin that contributed most of the asylum seekers, altogether 2434 
(52%) [23].  
Among the 2237 asylum seekers who fulfilled the inclusion criteria and were 
included in the study group, 1563 (70%) were males and 1447 (65%) were 18-34 
years of age (Table 1).  An abnormal X-ray was found in 314 persons, 2077 had a 
Mantoux  6 mm and 27 were included because of a positive QFT only.  Compared to 
those not included, the study group had significant fewer persons in the lowest and 
more in the middle and oldest age group, more were married, more came from 
Somalia, and more had a BCG scar (data not shown).  
 
Cases of tuberculosis 
By end May 2008, 28 cases of tuberculosis were diagnosed and none of them got 
treatment for latent tuberculosis after arrival in Norway.  The median time from 
arrival until notification was two months (range 0-27).  Thus, 15 patients were 
diagnosed within two months of arrival, and 17 within six months.  Eight patients 
were diagnosed later than one year after arrival (Table 2).  
Twenty two cases had M. tuberculosis confirmed by culture, one case M. 
Africanum, while one was culture negative and four had unknown bacteriology.  
There were 18 patients with pulmonary and eight with extra-pulmonary TB, while the 
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localization was unknown for the remaining two.  Somalian origin was associated 
with extra-pulmonary TB (data not shown).  Twelve of the 15 women with 
tuberculosis came from Somalia.  Their median age was 25 years (range 21-49).  
Mantoux  15 mm on arrival was found in 12 (43%) cases and Mantoux  10 mm in 
20 (69%) cases (Table 2).  Lack of a BCG vaccination scar was not associated with 
active TB (data not shown).  
In a univariate analysis for all cases of active TB, a positive association was 
found with a positive chest X-ray, Mantoux  15 mm, Mantoux  10 mm, female 
gender, and Somalian origin (Table 3).  In adjusted logistic regression models, gender 
and country of origin were entered into the model.  A positive association with active 
TB was found for female gender and Somalian origin when either Mantoux  10 mm, 
or Mantoux  15mm, or a positive chest X-ray were included (Table 4).   
 
The yield of screening 
Fifteen cases were detected within two months after arrival.  Twelve of the cases had 
positive X-ray findings when they arrived and 13 had symptoms of TB at the time of 
diagnosis.  There were twelve cases of pulmonary and two with extra-pulmonary TB 
and one with unknown localization.  Thirteen had a positive culture (Table 2 and 5).   
All cases diagnosed by screening were reported from hospitals in the Oslo 
area.  Of the 12 cases with an abnormal X-ray on arrival, six had visited the Central 
TB Clinic.   
Two cases were diagnosed from three to six months after arrival, one with 
pulmonary and one with extra-pulmonary TB, and one of them was confirmed by 
culture.  Eleven cases were diagnosed from eight to 27 months after arrival.  Five had 
pulmonary, five extra-pulmonary TB and one unknown localisation.  Nine patients 
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had the diagnosis confirmed by culture.  Three patients had an abnormal X-ray on 
arrival screening and 12 patients had a Mantoux  10 mm (Table 2 ).  
None of the two cases diagnosed four and five months after arrival had been 
examined at the Central TB Clinic.  However, one reported having symptoms on 
arrival. 
All three cases with an abnormal X-ray on arrival who were detected later than 
six months after arrival, had been examined at the Central TB Clinic just after arrival 
and were judged not to have TB disease at that time.  They were advised to have 
further follow-up if there were a future doubt about the diagnosis.  Thus, they 
probably have developed TB later.  Ten of the late cases were diagnosed at different 
hospitals around the country.  They had been referred from PHC due to clinical 
symptoms.  One case diagnosed after ten months had been referred from PHC to 
specialist for assessment of screening results following a move to an asylum seekers 
centre in the community. 
In univariate logistic regression of cases detected by screening or not, an 
abnormal X-ray showed an OR of 9.0 (1.6-50.7), while pulmonary TB vs. extra-
pulmonary TB detected by screening gave an OR of 6.0 (0.9-39.2), however, the last 
OR is not significant (table 5).  There were no other association between time of 
diagnosis and demographics or screening results. 
 
Discussion 
The total yield of the screening was 15 cases of TB.  Two cases were diagnosed 
between three and six months after arrival and were probably missed by the screening.  
The other 11 cases were not diagnosed as a part of the screening programme.  Cases 
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identified by screening more often had abnormal X-rays on arrival.  Female gender 
and Somalian origin increased the risk for TB disease. 
The TB prevalence in this high risk group was 15/2237 (0.7%) [25].  That prevalence 
was comparable to other studies of TB screening among immigrants where the 
prevalences ranged from 0.1.-1.2% [7-10].  
A major objective of the screening programme is to diagnose pulmonary TB 
as early as possible to minimize risk of transmission within the country.  This seemed 
to have been the case here as 12 of the 15 cases detected had pulmonary TB.  Through 
the match with the Tuberculosis Register we detected several cases diagnosed at 
different hospitals in the Oslo area.  However, we could not trace any information 
about referrals for these patients through the files at the National Reception Centre or 
the study forms.  Previously we have reported that 62% of persons with an abnormal 
X-ray on screening and 70% of those with parenchymal findings had been seen by a 
specialist [23].  Thus, we have reasons to believe that more cases had been referred to 
specialist than we were able to detect in our study. 
A pertinent question is whether cases that were detected later than two months 
after arrival could have been detected earlier or prevented.  One patient who was 
diagnosed four months after arrival had been ill since arrival.  And another who was 
diagnosed five months after arrival, and was found through contact tracing, had 
symptoms at the time of referral.  However, we do not know the time from symptoms 
till diagnosis for any of the others.  All the 11 patients who were detected later than 
six months after arrival had either abnormal X-rays or a positive Mantoux test at entry 
and should have been referred to a specialist or examined by PHC.  Seven had not 
been referred to or seen by a specialist to reach a conclusion about entry findings.  We 
believe that some cases could have been detected with active TB earlier or been given 
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treatment for latent tuberculosis if the guideline recommendations had been followed.  
However, the Norwegian guidelines do not give definite recommendations for 
treatment and a previously published study of the same cohort showed that only 30 
persons were treated for latent tuberculosis [26].  
Asylum seekers were not interviewed about symptoms on arrival, and 
registration of symptoms seems to be incidental.  Possibly, a medical interview could 
have raised suspicion for some of the cases, particularly the ones with extra-
pulmonary TB.  On the other hand, screening for TB in a Brazilian prison showed that 
1/3 of the TB cases denied any symptoms during an initial interview, and several 
patients with a cough of more than three weeks duration held that they had a “normal” 
cough [27]. 
As more cases found through screening in our study had abnormal X-rays and 
tended to have more pulmonary TB (Table 5), an abnormal X-ray was the main 
indication for an immediate follow-up.  There were no differences in the proportion 
with positive cultures between the groups diagnosed inside or outside the screening 
programme.  This could have been a spurious finding.  Others have reported that cases 
detected outside the screening programme showed an increase in the number of 
positive cultures [11].  
Other studies have also shown that regardless of any arrival screening there is 
an increased risk for active TB for several years after arrival.  However, all these late 
cases have been interpreted as incident ones [5, 6, 28].  This is particularly the case 
for extra-pulmonary TB [6]. 
Origin from Somalia was associated with an increased risk for active TB.  
That compares well with several other studies [5, 22, 29, 30].  There was also an 
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association between Somalian origin and extra-pulmonary TB, which also has been 
shown in a previous Norwegian study [31]. 
In our study females had a significant increased risk for active TB.  Further, 12 
of the 15 females with tuberculosis were from Somalia.  We have no information 
whether females from Somalia arriving in Norway have other risk factors.  Low 
numbers in the present study or other health seeking behaviours in their home country 
may explain why our results differ from other studies from developing countries 
where males have higher risk [32].  However, studies from Western countries at the 
time when TB was prevalent, showed increased risk for females of fertile age [32].  
We had data from the arrival screening for a complete cohort of asylum 
seekers where all subjects with positive findings on screening were matched with data 
from the National Tuberculosis Register.  However, we did not match those without 
positive screening results as they are not supposed to be followed up, and we have no 
data on numbers of study subjects that left Norway during the study period.  This may 
obviously have influenced the number of people who were available for analysis and 
made exact estimating of incidences impossible. 
Asylum seekers frequently change name and/or date of birth which may have 
given an artificial reduction in the matching procedure with the National Tuberculosis 
Register.  Also some underreporting of responses on study forms could have been 
caused by this change of names and birth dates.   
Smear results were not available for analysis because very few were reported 
with this information to the National Tuberculosis Register. 
Only persons with an abnormal X-ray or who had been traced at the National 
Reception Centre as referred to a specialist, were matched with the Central TB Clinic.  
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This procedure could have led to some underreporting of cases seen by specialist 
because a similar match was not done with other hospitals. 
We defined patients who were diagnosed before two months of arrival as 
detected by the screening programme.  Hence, misclassification of the cases may have 
led to over- as well as underestimation of the yield of the programme.  In most cases, 
the files at the Tuberculosis Register gave no clear answer whether the clinical 
examination was the result of screening or not.  Nor did they report the length of time 
between symptoms onset and the TB diagnosis.  Some late cases may have been 
reinfected after arrival in Norway, but infection rate within the country is generally 
low [1]. 
More cases were found and more referrals done than we were able to detect 
from the follow-up study.  Thus, in spite of an imperfect follow-up of screening 
results 15 of 17 TB cases were found through screening, most of which were 
pulmonary TB.  As a consequence of this study, we will stress that an immediate 
follow-up of all with an abnormal X-ray should be verified by a quality assurance 
system.  In cases of latent TB, treatment should always be considered.  Special 
measures for all asylum seekers from Somalia should also be considered.  
  Further studies are needed to assess cost-effectiveness of the screening 
programme. 
 
List of abbreviations used 
TB: Tuberculosis 
QFT: QuantiFERON® TB Gold 
PHC: Primary Health Care 
CI: Confidence Interval 
OR: Odds Ratio 
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Table 1: Numbers, percents and CI by demographics and screening results for study group and TB 
cases 
 Groups Study group N=2237 
 
TB cases 
N=28 
  Numbers (%) 95% CI Numbers (%) 95% CI 
18-34 years 1447 (65) 
 
63-67 22 (79) 
 
63-94 
35-49 years 656 (29) 
 
27-31 4 (14) 
 
1-27 
Age groups 
>50 years 134 (6) 
 
5-7 2 (7) 
 
-2-17 
Males 1563 (70) 
 
68-72 13 (46) 
 
28-65 Gender 
Females 674 (30) 
 
28-32 15 (54) 
 
35-72 
Married 1034 (46) 
 
44-48 10 (36) 
 
18-53 Marital status 
Not married 1203 (54) 
 
52-56 18 (64) 
 
47-82 
Iraq 224 (10) 
 
9-11 1(3.6) 
 
-3-10 
Somalia 457 (20) 
 
19-22 15 (54) 
 
35-72 
Russia 182 (8) 
 
7-9 4 (14) 
 
1-27 
Afghanistan 166 (7.4) 
 
6-9 1 (3.6) 
 
-3-10 
The five most 
frequent 
countries 
Serbia and 
Montenegro 
149 (6.7) 
 
6-8 2 (7.1) 
 
-2-17 
<6mm 146 (6.5) 
 
6-8 1 (3.6) 
 
-3-10 
6-9mm 680 (30) 
 
28-32 2 (7.1) 
 
-2-17 
10-14mm 760 (34) 
 
32-36 8 (29) 
 
12-45 
Mantoux test 
 15mm 637 (28) 
 
27-30 12 (43) 
 
25-61 
Abnormal X-
ray 
 314 (14) 
 
13-15 16 (57) 39-75 
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Table 3: Tuberculosis cases, univariate analysis 
 
    Univariate analysis 
 Case 
N=28 
Control 
group 
N=2209 
 OR 95%CI 
Age 18-34 22 1425  1(ref) 
Age 35-49 4 652  0.42 0.14-1.2 
Age  50 2 132  1.6 0.5-5.3 
Male 13 1550  1(ref) 
Female 15 659  2.7 1.3-5.7 
Unmarried 18 1016  1(ref) 
Married 10 1193  0.64 0.30-1.4 
Not from 
Somalia 
13 1767  1(ref) 
Somalia 15 442  4.6 2.2-9.8 
Mantoux  
10mm  
20 1377  4.0 1.2-13.4 
Mantoux 
 15mm 
12 625  2.8 1.2-6.3 
Abnormal 
X-ray 
16 298  8,6 4.0-18.3 
 
 
 
 
 
 
 
Table 4: Tuberculosis cases, multivariable analysis 
 Mantoux  10mm  Mantoux  15mm  Abnormal X-rays 
Variables OR 95% CI  OR 95% CI  OR 95% CI 
Male 1(ref)  1(ref)  1(ref) 
Female 2.9 1.2-6.8  2.8 1.2-6.6  2.6 1.2-5.7 
Not from 
Somalia 
1(ref)  1(ref)  1(ref) 
Somalia 4.0 1.7-9.4  4.2 1.8-9.8  4.7 2.2-10.1 
Mantoux  
10mm 
2.9 0.8-9.9  ----- -----  ----- ----- 
Mantoux 
 15mm 
----- -----  1.9 0.8-4.4  ----- ----- 
Abnormal 
X-ray 
----- -----  ----- -----  9.7 4.5-21.2 
Three multivariable models where included variables are Somalia, gender, and either Mantoux  
10mm, Mantoux  15mm or an abnormal X-ray 
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Table 5. Univariate analysis: cases detected by screening or not, by 
demographics, screening results, and characteristics 
 Detected 
by 
screening 
 
n=15 
Missing 
values 
Not 
detected 
by 
screening 
n=13 
Missing 
values 
OR 95% CI 
18-34 years 12  10  1.2 0.20-7.3 
 35 years 3  3    
       
Females 7  8  0.55 0.12-2.5 
       
Somalia 7  8  0.55 0.12-2.5 
       
Mantoux 
>10 
8 (2) 5 12 (1) 0 0.33 0.03-4.3 
Mantoux 
>15 
5 (5) 5 7 (6) 0 0.86 0.16-4.5 
       
Abnormal 
X-rays  
12 3 4 9 9.0 1.6-50.7 
TB pulm 12 (2) 1 6 (6) 1 6.0 0.92-39.2 
Culture 
positive 
13 (1) 2 10 (0) 3 0.001  
Brackets indicates negative numbers when there are some missing values  
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